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ABSTRACT 
 
 
Phosphonate and phosphinate natural products possess a range of biological 
activities as a result of their ability to mimic phosphate esters or tetrahedral intermediates 
formed in enzymatic reactions involved in carboxyl group metabolism. The widespread 
use in medicine and agriculture of these compounds has resulted in active researches, 
revealing novel biochemistry behind their metabolic pathways. One of such compounds, 
PTT, contains unusual amino acid phosphinothricin attached to two alanine residues. The 
peptide bond formation and methylation on phosphorus in PTT are key steps in PTT 
biosynthesis, however, the exact timing of these transformations was not known. To 
provide insights into these questions, a heterologous expression system was developed 
for PhsA, the first of three NRPS proteins involved in PTT biosynthesis, and kcat/Km value 
for the ATP-pyrophosphate exchange activities of the purified protein with putative 
substrates were determined. The kcat/Km value for L-N-AcPT was 7-fold higher than for 
D,L-N-AcDMPT, suggesting the former might be the physiological substrate. Both 
substrates were loaded onto the thiolation domain of PhsA as demonstrated by FTMS. 
The possible implications of these findings for the timing of the methylation reaction are 
discussed. Another phosphonate presented here is antibiotic dehydrophos, which contains 
a unique methyl ester of a phosphonodehydroalanine group. Since the dianionic form of 
phosphonates at pH 7 poses a drawback with respect to their ability to mimic 
carboxylates and tetrahedral intermediates, esterification of a phosphonate group by 
SAM-dependent methyltransferase, DhpI would provide a solution to alleviating the high 
charge state, and thus improve the bioavailability of phosphonates. This study describes 
expression, purification and reconstitution of DhpI in vitro. Also, substrate scope and X-
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ray crystal structure of DhpI are also discussed. The enzyme utilizes S-
adenosylmethionine to methylate a variety of phosphonates including 1-HEP, 1,2-DHEP, 
and Ac-1-AEP. Kinetic analysis showed that the best substrates are tripeptides containing 
as C-terminal residue a phosphonate analog of alanine suggesting the enzyme acts late in 
the biosynthesis of dehydrophos. These conclusions are corroborated by the X-ray 
structure that reveals an active site that can accommodate a tripeptide substrate. 
Furthermore, the structural studies demonstrate a novel conformational change brought 
about by substrate or product binding. Interestingly, the enzyme has low substrate 
specificity and was used to methylate the clinical antibiotic fosfomycin and the clinical 
anti-malaria candidate fosmidomycin, showing its promise for applications in 
bioengineering. Overall, the findings in this thesis provide valuable insights in Nature’s 
strategy for making novel phosphonates which can be further developed into applications 
in novel drug discovery.  
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CHAPTER 1: INTRODUCTION 
 
1.1 – Antibiotics Background 
Antibiotics have been enjoying the reputation of being the most successful 
chemotherapy developed in the twentieth century. Natural products with antimicrobial 
activity are produced by both fungi and bacteria as secondary metabolites used to combat 
foreign microbes.1 Exploiting natural products led to the discovery of many new 
antibiotics during the 1940s-1960s, followed by extensive interrogations of these novel 
chemical scaffolds to tailor them into drugs with improved pharmacokinetics.2 The major 
targets of current commercial antibiotic drugs are cell wall biosynthesis, protein 
biosynthesis, and DNA gyrases (Table 1.1).1,3  
The widespread use of antibiotics in the last century has resulted in the emergence 
of antibiotic resistance (Table 1.1). Antibiotic resistance is almost inevitable as there is a 
continuous evolutionary pressure on microorganisms which introduce genetic mutations 
at random; selection for resistant mutants in the population results in resistance. Ever 
since the advent of antibiotics for the treatment of bacterial infections, antibiotic 
resistance has been a continuing problem and the search for new antibiotics has been of 
primary importance.4 Multidrug-resistant bacteria that cannot be treated with currently 
available drugs are emerging at an alarming rate, posing a threat to mankind. In fact, 
infectious diseases are the major causes of death worldwide.5 Yet industrial efforts to 
discover novel antibiotics have declined markedly. Causes for decreased support of 
antibiotics research, among others, include lack of industry productivity, increasing size 
2 
of clinical trials, low projected profits for non-chronic diseases, and increased generic 
competition.6  
In order to overcome the imminent threat of antibiotic resistance, new approaches 
for antibiotic discovery must be sought, that embrace modern chemistry, bioinformatics, 
and biological tools. As shown in Table 1.1, most of the antibiotics that are currently in 
clinical use are derived from natural products discovered during the heydays of natural 
product discovery. These compounds are usually produced by soil bacteria (e.g. 
Streptomyces) that can be cultured in a laboratory setting.5 Screening for strains capable 
of producing biological activities, optimization of culturing conditions for antibiotic 
production, isolation of the natural product responsible for the biological activity, and 
subsequent structural identification and synthesis of the complex natural products are 
highly demanding processes. Accordingly, modern drug discovery has turned away from 
the labor-intensive and costly natural product research to target-based combinatorial 
chemical approaches. These changes, brought by the advances in high-throughput 
screening and ever-increasing genomic information, also provided new opportunities for 
revolutionizing antibiotic mining strategies. At present, the pursuit of novel biological 
targets by high-throughput-screening approaches has not been very successful so far, and 
still needs to overcome many hurdles.4 These challenges are also reflected in the renewed 
interest in natural product antibiotics research in recent years, which emphasizes finding 
new targets using reverse-genomics as well as revisiting old compounds for further 
investigation. This thesis presents efficient methodology by which a class of naturally 
produced antibiotics, phosphonates and phosphinates, can be discovered and their 
biosynthesis investigated by reconstitution of the enzymatic reactions.  
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Class of 
Antibiotics Derivatives Bacterial Target 
Year 
Deployed 
Resistance 
Observed 
Sulfonamides Sulfanilamide Sulfadiazine 
Fatty acid 
metabolism 1930s 1940s 
Quinolones Ciprofloxacin Ofloxacin 
DNA replication 
(gyrase) 1960s 1980s 
Oxazolidones Cycloserine Linezolid Protein synthesis 2000 2001 
Penicillins Amoxicillin Ampicillin 
Cell wall 
biosynthesis 1943 1946 
Aminoglycosides Gentamicin Streptomycin Protein synthesis 1943 1959 
Tetracyclines Tigecycline Minocycline Protein synthesis 1948 1959 
Macrolides Clarithromycin Erythromycin Protein synthesis 1952 1988 
Glycopeptides Vancomycin Telavancin 
Cell wall 
biosynthesis 1956 1988 
Cephalosporins Cefaclor Cefuroxime 
Cell wall 
biosynthesis 1960s 1960s 
Lipopeptide Daptomycin Surfactin Cell membrane 2003 2004 
 
Table 1.1 Different classes of antibiotics and their derivatives. The shaded antibiotics are 
derived from synthetic lead compounds while the other antibiotics are derived from 
natural products.1,3,7  
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1.2 – Phosphonates and Phosphinates 
Phosphonic and phosphinic acids (Figure 1.1) contain carbon-phosphorus (C-P) 
bonds, and are known to exert important biological activities as they are structural 
analogues of naturally prevalent molecules such as carboxylic acids and phosphate esters 
and anhydrides. Some known phosphonate and phosphinate compounds isolated from 
Nature have proven to act as potent competitive inhibitors against many enzymes. Also 
when chosen appropriately the inhibitory activities of these compounds generally do not 
affect enzymatic processes taking place in humans, making them attractive drug 
candidates. Despite the demonstrated utility of phosphonates as therapeutics and 
agricultural chemicals,8 until very recently our knowledge of their biosynthesis had been 
very limited.  Recent progress in elucidating biogenesis of C-P compounds in a 
collaborative effort named “Mining Microbial Genomes for Novel Antibiotics” at the 
Institute for Genomic Biology of University of Illinois has resulted in the discovery of 
many important metabolic pathways; moreover it has shown that there are many C-P 
natural products yet to be discovered. 
 
 
Figure 1.1 Chemical structure and formal oxidation state of compounds containing 
phosphorus. Phosphonates contain one bond of phosphorus to carbon or hydrogen, and 
phosphinates contain two bonds between phosphorus and carbon or hydrogen. 
Phosphates have the highest oxidation state of +5.  
5 
While phosphate esters are unstable, phosphonates and phosphinates are highly 
resistant to hydrolysis and enzymatic cleavage. These characteristics confer phosphonates 
and phosphinates the ability to inhibit a wide variety of cellular transformations adaptable 
to medicinal and agricultural applications. Notable examples of these compounds include 
aminophosphonopentenoic acid (APPA), a strong antifungal and antibacterial agent 
which inhibits threonine synthesis;9 fosfomycin, an FDA-approved antibiotic;10  
phosphinothricin tripeptide (PTT), a widely used herbicide;11 FR-900098 and 
fosmidomycin, which inhibit DXP reductioisomerase;12,13 and K-26, a strong inhibitor of 
angiotensin-converting enzyme (Figure 1.2).14 Many efforts have focused in recent years 
to isolate the biosynthetic gene clusters of these compounds and to characterize their 
biosynthetic pathways,8 which resulted in partial elucidation of biosynthetic steps 
involved in production of some biochemically and therapeutically important C-P 
containing compounds shown in Figure 1.3. Although naturally occurring C-P 
compounds are also found in larger phosphonate-containing polymers with structural 
functions in the form of phospholipids, polysaccharides, and proteins, the focus of this 
thesis will be confined to small molecule C-P compounds exhibiting antibiotic activities.  
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Figure 1.2 Examples of natural phosphonic and phosphinic acids. These C-P bond 
containing compounds (blue) can inhibit target enzymes (in parentheses, black) as 
structural mimics of enzyme substrates and intermediates (red). Shown here are (A) 
mimics of phosphate esters (APPA, FR900098 and fosmidomycin), (B) a mimic of 
carboxylate group (1-aminoethyl phosphonate), and (C) a mimic of the tetrahedral 
intermediate generated by ammonia addition during glutamine synthetase activity 
(phosphinothricin).  
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The increased available information on the biosynthesis of C-P compounds in 
recent years8 demonstrated that the phosphorus bond formation in phosphonate and 
phosphinate biosynthesis is accomplished by the same initial step catalyzed by 
phosphoenolpyruvate (PEP) mutase (Figure 1.3).8 This reaction is thermodynamically 
unfavorable and is often coupled to a subsequent decarboxylation reaction catalyzed by 
phosphonopyruvate (PnPy) decarboxylase (Figure 1.3).8 The reliance of the biosynthetic 
pathways of C-P compounds on PEP mutases (PepM) has been used to screen and 
identify gene clusters for phosphonate production. Briefly, degenerate primers for pepM 
were designed for polymerase chain reaction (PCR), which can successfully identify 
phosphonate biosynthetic gene clusters from the genomic DNA of a known producing 
strain and even from uncharacterized environmental samples.8 In fact, gene clusters of 
several prominent C-P compounds such as PTT,15 dehydrophos,16 fosfomycin,10 and 
FR90009812 were identified in producing strains using this approach. 
Understanding the strategies that Nature employs to make novel phosphonates not 
only gives an insight in their biogenesis but is a key to the improvement in production 
and potential downstream combinatorial biosynthesis. Also, given the broad biological 
activities for the currently known phosphonates reported, investigation of unexplored 
phosphonates would pave a way to discovery of novel compounds with high potency. 
The exotic functional groups present in these compounds can serve as inspirations for 
synthetic chemists designing novel chemical scaffolds and also for finding new modes of 
action. Furthermore, their biosynthetic pathways include a number of unprecedented 
enzymatic reactions worth investigating, and these enzymes may be developed into 
biocatalysts.  
9 
1.3 - Nonribosomal Peptide Synthesis  
Natural product antibiotics are often synthesized as short peptides by 
multienzyme complexes called nonribosomal peptide synthetases (NRPSs) instead of 
being synthesized on the ribosome. Because they are not limited by tRNA synthetases, 
nonproteinogenic amino acids can be incorporated into a peptide product, and various 
tailoring reactions can take place to give rise to a peptide decorated with various 
functional groups.17 Examples of peptide antibiotics synthesized by NRPSs include 
tyrocidine, gramicidin S, bacitracin, vancomycin, and daptomycin (Figure 1.4).17 The 
lengths of these peptides can vary from 2 to 20 amino acids, and can be produced as 
macrocyclic or linear peptides.18 
NRPS assembly lines consist of multi-domain enzymes organized into modules. 
Each module is responsible for incorporating one amino acid (sometimes several) 
building blocks into the growing peptide chain. Generally there is a chain initiation 
module at the N-terminus, followed by elongation modules, and finally a termination 
module at the C-terminus (Figure 1.5). In elongation modules, minimal compositions are 
condensation (C), adenylation (A), and thiolation (T) domains, the latter also known as 
peptidyl carrier protein (PCP). An A domain is responsible for recognizing and activating 
the amino acid substrate, and therefore acts as a gate keeper in selecting very specific 
amino acids. The amino acid is activated as aminoacyl adenylate in the presence of ATP 
and Mg2+ which resembles the activation process for tRNA synthetase in ribosomal 
peptide synthesis. Prior to loading the activated aminoacyl adenylate, the T domain 
undergoes posttranslational modification known as phosphopantetheinylation, a priming 
process by which the 4’-phosphopantetheine (PPant) group from acetyl CoA is 
10 
transferred by a PPant transferase to a highly conserved active site serine residue in the T 
domain (Figure 1.5). This PPant group is a handle-like long chain structure with a 
terminal thiol group which covalently tethers the aminoacyl adenylate to the T domain 
via a thioester bond. The PPant arm is also required for flexible positioning of the amino 
acid attached to the T domain of one module to near the C-domain of the next module, 
after which thiotemplate-guided peptide bond formation occurs in the C domain. After 
the elongation of the entire peptide is completed, the final product is released from the 
enzyme complex by a thioesterase (Te) domain. Modifications to amino acids can take 
place by various reactions such as epimerization (E) and N-methylation (N-Met) while 
still bound to the enzymes by tailoring domains in NRPSs or they can be achieved after 
the peptide is released from the synthetase. 
11 
 
    
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Examples of peptide antibiotics assembled by nonribosomal peptide 
synthetases (NRPSs). 
Tyrocidine 
Gramicidin S 
Bacitracin 
Vancomycin 
Daptomycin 
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1.4 – SAM-dependent Methyltransferases  
Methylation is one of the most common reactions in biology, required in the 
biosynthesis of hormones and neurotransmitters, DNA maturation, and esterification of 
carboxylate groups in certain proteins.19 The reaction is known to occur in two steps of 
complexation between a donor and an acceptor molecule followed by methyl transfer in 
an associative mechanism via a single transition state (Figure 1.6A).20 Among known 
methyl donors, S-adenosyl-L-methionine (SAM or AdoMet) is the most prevalently used 
cofactor in Nature, with a chemical structure shown in Figure 1.6B. Upon transfer of the 
methyl group, AdoMet is transformed to the more stable S-adenosyl-L-homocysteine 
(SAH or AdoHcy).  
SAM-dependent methyltransferases catalyze nucleophilic attack of oxygen, 
nitrogen, sulfur, and carbon nucleophiles on the sp3 carbon (of the methyl group) in a 
classic SN2 fashion, often requiring Mg++ as cofactor.21,22 Structurally, mostly known 
SAM-dependent methyltransferases with reported crystal structures share similar core 
structures, consisting of a typical α/β fold similar to the nucleotide-binding motif 
(Rossman fold).23 The active site is found between the SAM-binding domain and 
substrate-binding domain of the enzyme. Most SAM-dependent O-methyltransferases 
catalyze methylation of carboxylate or hydroxyl groups, and O-methylation on 
phosphonic acid has not been reported in the past. Conversion of phosphonates to a 
methyl ester reduces the negative charge on the molecule making it more efficient for cell 
diffusion.  
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Figure 1.6 Methyl transfer reaction. (A) Concerted mechanism of a methyl transfer 
reaction (B) The chemical structure of SAM. The stereochemistry at the sulfur atom is 
important for the biological activity of SAM.24  
A 
B 
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1.5 – Summary 
There is a continued need for development of new antibiotics due to ever-
increasing antibiotic resistance towards currently available antibiotics. In the past, 
naturally occurring biologically active compounds have proven to be great drug 
candidates and still continue to be a major reservoir for novel antibiotics. Recent progress 
in investigation of the biosynthesis of phosphonate antibiotics has revealed aspects of 
phosphonate metabolism in microorganisms, and the enzymes involved have provided a 
wealth of interesting and unique chemistry. Often the peptide bond formation in the 
phosphonate and phosphinate biosynthesis involves catalysis by NRPSs introducing a 
vast number of unique nonproteinogenic amino acids. This thesis will discuss the 
experiments conducted with one such enzyme involved in the biosynthesis of bialaphos 
as described in Chapter 2. In addition, an interesting SAM-dependent methyl transfer 
reaction is found in the biosynthesis of the phosphonate dehydrophos possibly to alleviate 
unfavorable high negative charge in the phosphonic acid. Investigations into the 
biosynthetic pathway of dehydrophos are presented in Chapter 3 whereas studies of the 
methyl transferase are described in Chapter 4.  
17 
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CHAPTER 2: STUDY OF A NONRIBOSOMAL PEPTIDE SYNTHETASE 
INVOLVED IN PHOSPHINOTHRICIN TRIPEPTIDE BIOSYNTHESIS*  
 
2.1 – Introduction 
Phosphinothricin tripeptide (PTT, also called bialaphos, Figure 2.1) is produced 
by Streptomyces viridochromogenes and Streptomyces hygroscopicus.21 This natural 
product consists of an unusual phosphinic acid phosphinothricin (PT), which contains a 
unique carbon-phosphorus-carbon moiety, and two alanines. PTT enters a bacterial cell in 
a Trojan-horse manner via an oligopeptide transporter. Once inside the cell, the active PT 
is released by universal peptidase activity.22  
This unusual P-methylated amino acid is a structural mimic of a tetrahedral 
intermediate formed during nucleophilic addition of ammonia to glutamic acid in the 
glutamine synthetase reaction.23 Complete inhibition of glutamine synthetase activity 
results in ammonia build-up that is toxic to plants, and in bacteria this inhibition leads to 
glutamine shortage (Figure 2.2). PTT is widely used as an herbicide under the tradename 
Herbiace and the ammonium salt of PT is the active ingredient in BASTA. Transgenic 
plants engineered to contain the PT-resistance gene (pat in S. viridochromogenes,24 
Figure 2.1, or bar in S. hygroscopicus25) have found widespread use in agriculture in the 
form of LibertyLink genetically modified crops such as corn, cotton, soybean and canola.  
 
 
 
 
                                                 
* Reproduced in part with permission from “In Vitro Characterization of a Heterologously Expressed 
Nonribosomal Peptide Synthetase Involved in Phosphinothricin Tripeptide Biosynthesis.” Biochemistry, 
2009, 48, 5054-5056. Copyright 2009 by the American Chemical Society.  
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Figure 2.1 The currently accepted biosynthetic pathway for PTT is shown with solid 
arrows. An alternative pathway in which AcDMPT is first methylated and then 
incorporated into the tripeptide is depicted in dashed arrows. 
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Figure 2.2 Schematic representation of PTT mode of action in both plant and bacterial 
cells.  
 
 
 
In recent years, the PTT biosynthetic gene cluster in S. viridochromogenes has 
been fully sequenced26,27 and part of the cluster of S. hygroscopicus has also been 
reported.28,29 The final steps in PTT biosynthesis include tripeptide assembly as well as 
installation of the methyl group on the phosphorus atom (Figure 2.1).30-32 PhpK-catalyzed 
P-methylation, which endows PTT its characteristic phosphinate moiety, has been of 
great interest due to the structural importance and agricultural applications of this 
compound.33 However, the exact timing of the methyl transfer step, whether before, 
during or after peptide assembly, is currently unknown.34 A mutant in phsA, 
encoding one of three nonribosomal peptide synthetase proteins in the PTT gene cluster 
(PhsA, PhsB, and PhsC),30,32,35 accumulated N-acetyldemethylphosphinothricin 
(AcDMPT) suggesting that this phosphinate amino acid is the substrate for PhsA.36,37  
22 
 From the amino acid sequence, it has been suggested that PhsA is an initiation 
module in the nonribosomally synthesized tripeptide.30 From the sequence homology 
analysis, PhsA was shown to be comprised of an adenylation (A) domain that activates 
the N-terminal phosphinic acid scaffold to its corresponding aminoacyl adenylate, a 
thiolation (T) domain that covalently tethers the amino acid to the phosphopantetheine 
(PPant) arm of the peptide carrier protein, and a putative N-terminal thioesterase (Te) 
sequence motif of unknown function (Figure 2.3A,C).35 After charging of the phosphinate 
amino acid onto PhsA, the two peptide bond forming events are catalyzed by the 
condensation domains of PhsB and PhsC, each loaded with alanine (Figure 2.3B).30,32 
The order of peptide bond formation and how the final product is released from the 
peptide carrier protein (PCP) of PhsB/PhsC is currently not clear. The final release step 
could involve the N-terminal thioesterase (Te) motif of PhsA or two stand-alone type II 
thioesterases in the PTT gene cluster (Figure 2.3C).35 
Keller and Wohlleben and their coworkers isolated the native PhsA enzyme from 
S. viridochromogenes in small quantities.30 Sufficient protein was obtained to study the 
activity of the enzyme by ATP-pyrophosphate (PPi) exchange assay, demonstrating that 
AcDMPT was utilized most efficiently under the conditions employed, but that N-acetyl 
phosphinothricin (AcPT) was also a substrate. Attempts to express the enzyme in 
Escherichia coli to obtain larger quantities of protein were not successful. Collectively, 
these studies suggest the order of events shown in solid arrows in Figure 2.1. The 
observed activity of charging PhsA with AcDMPT suggests the possibility that the 
methylation step is a tailoring reaction that takes place while AcDMPT is tethered to the 
PPant arm of PhsA (or PhsB/PhsC). 
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  In order to investigate the molecular details for this step, the possibility to express 
active PhsA in E. coli has been revisited. In this study, we show that a fusion protein of 
PhsA to maltose binding protein (MBP) was expressed in soluble form and that it was 
active in ATP-PPi exchange assays. In vitro phosphopantetheinylation of apo-PhsA by 
PPant transferase, Sfp, from Bacillus subtilis was investigated using various detection 
methods. The kinetic parameters for ATP-PPi exchange were determined for a series of 
substrates including AcDMPT for which synthetic preparation had not been reported 
before the start of this work. In addition, formation of a covalent thioester linkage of 
loaded amino acid substrate to the PPant group of the T domain was assessed using 
Fourier-Transform mass spectrometry (FTMS). The results of this study as well as 
previous studies by Seto and coworkers33,34 suggest that an alternative pathway in which 
AcDMPT is first methylated cannot be ruled out (dashed arrows, Figure 2.1). 
 
2.2 – Results 
2.2.1. Heterologous Expression of PhsA  
Initial efforts to express PhsA as an N-terminal His6-tagged protein in E. coli 
BL21 (DE3) by cloning the phsA gene from genomic DNA of S. viridochromogenes 
DSM 40736 produced insoluble protein. Optimization of expression conditions in an 
attempt to produce more soluble PhsA included variations in induction conditions as well 
as co-expression of PhsA with chaperone proteins using commercially available pG-
KJE8 plasmid, which co-expresses the DnaK-DnaJ-GrpE-GroES-GroEL chaperone 
proteins.38 Other attempts in collaboration with the Kelleher group including conjugative 
transformation of S. lividans with the plasmid and cloning into a C-terminal His6-tag 
25 
system met with little success. It is interesting to note, however, that His6-PhsA with an 
undesired mutation at the active site serine residue (S579F) obtained from one of the 
clones turned out to be more soluble and its purification could be achieved using Ni-
affinity column chromatography (data not shown). It is tempting to speculate that the 
mutation results in a fold that resembles the holo form of the enzyme, which is expected 
to be more stable. Finally, the phsA gene was inserted into the pMAL-c2x vector to 
introduce MBP as a fusion at the N-terminus. Overexpression of PhsA as an MBP fusion 
in E. coli BL21 resulted in the production of a significant amount of soluble protein. 
However, after purification of the MBP-fusion protein by amylose affinity 
chromatography, the MBP-PhsA was isolated in a partially pure form. Truncated proteins 
were visualized via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), which were initially suspected to originate from premature termination of phsA 
translation due to rare codons in phsA (namely CCC for proline and CGG for arginine) 
that E. coli does not translate well. Therefore E. coli Rosetta 2 BL21 strain, which 
supplements tRNAs for these rare codons, was used for expression instead. Nevertheless, 
the truncated proteins still remained before and after the purification. Their continued 
presence suggests that they may have formed from the proteolytic cleavage of PhsA. To 
improve the purification, the malE-phsA fragment was cloned into pET28b and MBP-
PhsA-His6 protein was heterologously expressed in E. coli. Rapid purification of the 
resulted fusion protein by Ni-NTA chromatography followed by HiTrap Q HP ion-
exchange chromatography yielded 7 mg of intact protein per liter of culture (Figure 2.4). 
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Figure 2.4 Heterologous expression of PhsA in a soluble form. A construct which 
expresses an N-terminal MBP fusion of C-terminally His6-tagged PhsA allowed isolation 
of PhsA in a soluble form. 
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2.2.2. In Vitro Phosphopantetheinylation of PhsA 
As isolated, the recombinantly expressed MBP-PhsA-His6 protein did not contain 
detectable amounts of the phosphopantetheine arm as monitored by FTMS. Two 
experiments were performed to examine the in vitro phosphopantetheinylation of MBP-
PhsA-His6 by Sfp (Figure 2.5A), a highly promiscuous PPant transferase from the 
surfactin biosynthetic operon of B. subtilis. In the first experiment†, the fluorophore-
carrying coenzymeA (CoA) analogue BODIPY-FL-N-(2-aminoethyl)maleimidyl-S-CoA 
(BODIPY-CoA, Figure 2.5B) was employed to install a fluorescently labeled PPant 
group on the active site serine residue in the PhsA T domain, which could be readily 
detected spectrofluorometrically. The samples of PhsA that were treated with Sfp and 
BODIPY-CoA were analyzed by SDS-PAGE and visualized by coomassie blue staining, 
as well as by fluorescence spectroscopy (Figure 2.5C). When Sfp was co-incubated with 
PhsA in the presence of BODIPY-CoA, PhsA could be spectrofluorophotometrically 
detected, showing the successful transfer of the PPant group onto PhsA. In a second 
experiment 3H-acetyl-CoA was utilized as co-substrate, resulting in a time-dependent 
increase in the level of radiolabeled phosphopantetheinyl group from 3H-acetyl CoA to 
MBP-PhsA-His6. Maximum incorporation of tritium was achieved after less than 15 min 
and was nearly stoichiometric (Figure 2.5D), confirming that Sfp converts apo-MBP-
PhsA-His6 to its holo form with high efficiency. 
                                                 
†  In vitro phosphopantetheinylation experiment by in-gel fluorescence labeling was performed in 
collaboration with Bradley S. Evans from the laboratory of Professor Neil L. Kelleher (Department of 
Chemistry, UIUC).  
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Figure 2.5 In vitro phosphopantetheinylation of MBP-PhsA-His6. (A) Conversion of apo 
PhsA to its holo form by the PPTase Sfp. (B) Chemical structure of BODIPY-CoA. (C) 
In-gel fluorescent labeling. SDS-PAGE of reaction mixture after coomassie blue staining 
(left) and when visualized at 520 nm (right). Lane 1, protein standard; lane 2, negative 
control with only MBP-PhsA-His6; lane 3, MBP-PhsA-His6 treated with BODIPY-CoA; 
lane 4, MBP-PhsA-His6 treated with BODIPY-CoA and Sfp. (D) Time-dependent 
incorporation of tritium into MBP-PhsA-His6 during incubation with Sfp.  
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2.2.3. Syntheses of PhsA Substrate Analogues 
The previous investigation of the substrate scope of native purified PhsA showed 
that both AcDMPT and AcPT exhibited significant ATP-pyrophosphate exchange 
activities with AcPT having slightly lower activity (74%).30 These studies were 
performed at a substrate concentration of 667 μM (U. Keller, personal communication). 
In order to better understand the substrate scope of this enzyme at physiological 
conditions, it was desired to examine the initial rates of the enzymatic reaction at varying 
concentrations of the substrate analogs.  
In this study, we obtained sufficient amounts of protein for full kinetic 
characterization with potential substrates and substrate analogues (Figure 2.6). These 
compounds were prepared by chemical synthesis by Dr. Gongyong Li‡ from the van der 
Donk group and myself. AcDMPT was synthesized in seven steps starting from L-
methionine in 11% overall yield (Figure 2.7A). In this synthesis, L-methionine was first 
alkylated with bromoacetic acid followed by attack of the carboxylate oxygen onto the β-
carbon of the sulfonium salt, resulting in homoserine lactone 1. This lactone was 
brominated with hydrobromic acid in the presence of acetic acid to produce bromide 2. 
The carboxyl group of this compound was converted to its methyl ester 3 in hydrochloric 
methanol, followed by acetylation of the amino group to yield fully protected compound 
4. The bromide was treated with sodium iodide, and the resulting iodide 10 was reacted 
with bis(trimethylsilyl)phosphonite (BTSP) generated in situ from the reaction of 
ammonium hypophosphite and hexamethyldisilazane.39 The ammonium salt 11 was 
reacted with sodium hydroxide followed by purification on Dowex resin to obtain the 
                                                 
‡  Dr. Gongyong Li prepared AcDMPT. I participated in the synthesis of AcDMPT by preparing the 
intermediate 3 for the downstream steps performed by Dr. Li.  
30 
desired compound 12. Due to the low reaction yield, difficulty in purification of the 
product, as well as involvement of the highly pyrophoric compound BTSP in the 
phosphination step by Arbuzov-type reaction, an alternative method for AcDMPT 
preparation was explored (Figure 2.7B). In this method, radical addition of phosphite to 
the alkene 7 catalyzed by triethylborane, was achieved.40 This step proceeded with a high 
yield of 83% and included a more efficient purification step, and thus for large scale 
production of AcDMPT required in the enzymatic assay, the second route (Figure 2.7B) 
was employed.  
  
 
 
 
 
Figure 2.6 Acetylated amino acid substrate analogues used in the PhsA enzymatic assay.  
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Figure 2.7 Synthesis of AcDMPT. (A) Original reaction scheme in which Arbuzov-type 
reaction of the iodide with BTSP was used. (B) Alternative method in which radical 
addition of phosphite to the alkene 7 was employed to introduce the phosphinate. 
A 
B 
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AcPT was prepared by acetylation of commercially available D,L-PT by reaction 
with acetic anhydride and potassium carbonate. Previous studies have shown that the 
acetylated form of the amino acid substrate is essential for PhsA activity,30,33 and thus 
various other amino acids which are structurally similar to AcDMPT, including L-(+)-2-
amino-4-phosphonobutyric acid (L-AP-4), L-glutamate, L-aspartate, and fluorinated L-
AP-4§, were all acetylated (Figure 2.6) prior to testing for activity with PhsA. With the 
exception of AcPT, which was prepared as a racemic mixture, all substrate analogues 
were enantiomerically pure. 
 
2.2.4. Determination of the Substrate Scope of Adenylation Activity by PhsA 
The substrate set was used to probe PhsA activity by the ATP-PPi exchange assay 
using a published protocol.41 At 2 mM concentrations, L-N-AcAsp, L-N-AcAP4 and 
fluorinated L-N-AcAP4 showed very low activity and were not investigated further. On 
the other hand, L-N-AcGlu, L-AcDMPT, and D,L-AcPT showed significant ATP-PPi 
exchange activity and the substrate concentration dependence was further investigated. 
The initial exchange rates (<13% conversion) were plotted against substrate 
concentration as depicted in Figure 2.8. It has been noted for other investigations into the 
kinetics of the ATP-PPi exchange reaction that the unlabeled reactants very rapidly 
establish an equilibrium and hence that the observed rate of exchange is the equilibrium 
rate of production of radiolabeled ATP from labeled PPi (Figure 2.9). As such, although 
the ATP-PPi exchange reaction provides insights into enzyme specificity, it is not 
straightforward to interpret its kinetics in the framework of the Michaelis-Menten 
equation.42 However, because of the difficulties associated with measuring direct rates of  
                                                 
§ Dr. Xingang Zhang from the van der Donk group provided fluorinated L-AP-4. 
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Figure 2.8 Concentration dependence of the observed initial rates of amino acid-
stimulated ATP-pyrophosphate exchange. The lines were obtained by fitting the data to 
the Michaelis-Menten equation. (A) Initial rate of D,L-AcPT (red curve) compared to that 
of L-AcDMPT (blue curve) when the reaction was carried out by apo-MBP-PhsA-His6. 
When the substrate concentration was less than 400 μM, the initial rate of D,L-AcPT is 
higher than that of L-AcDMPT. (B) Apo-MBP-PhsA-His6 ( ) and holo-MBP-PhsA-His6 
( ) with D,L-AcPT. (C) Apo-MBP-PhsA-His6 with L-AcDMPT (  ) or L-N-AcGlu ( ), 
and holo-MBP-PhsA-His6 with L-AcDMPT (  ) or L-N-AcGlu ( ).  
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Figure 2.9 The ATP-pyrophosphate exchange assay. (A) Formation of the radiolabeled 
ATP monitored by separation of the radioactive species (i.e. ATP, ADP, and PPi) by thin 
layer chromatography (TLC) followed by analysis with a phosphorimager. When a poor 
substrate analogue (fluorinate L-AP-4, on the left) was used little amount of radiolabeled 
ATP was detected. When AcDMPT was used instead (on the right), formation of 
radiolabeled ATP was very high. (B) The amount of radiolabeled ATP was plotted 
against time to obtain the initial rate.  
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adenylation due to instability of the product as well as very tight binding of the 
aminoacyl adenylate by A-domains,43,44 the ATP-PPi exchange rate has been frequently 
used to provide insights into the substrate selectivities of adenylation.43-48 Importantly, in 
cases where adenylation could be measured directly and were compared with the rates of 
ATP-PPi exchange, very similar substrate selectivities were observed.43 
In addition to the expected exchange of 32P from pyrophosphate into ATP, small 
amounts of radiolabeled ADP and trace amounts of Pi were also observed, as has been 
seen in other studies of adenylation domains. ADP is typically not identified using the 
charcoal adsorption method as both ATP and ADP are adsorbed to the charcoal. The 
formation of these additional products was dependent on both PhsA and substrate. 
Inclusion of these radiolabeled products resulted in the same trends (larger apparent kcat 
for AcDMPT, smaller apparent Km for AcPT) as omitting them from the analysis.42 For 
the system under investigation here, at high concentrations, the observed exchange rate 
for AcDMPT (125 min-1, Table 2.1) was larger than that for AcPT (84 min-1), consistent 
with previous results.30 However, surprisingly the apparent Km values of the two potential 
natural substrates, AcPT and AcDMPT, showed that at low substrate concentrations 
AcPT is the preferred substrate for amino acid-stimulated ATP-PPi exchange (Table 2.1). 
This preference is even more pronounced when considering that AcPT is a mixture of 
enantiomers whereas AcDMPT was stereochemically pure. The ability of the A domain 
to recognize the substrates and activate them by adenylation was not dependent on the 
state of the T domain (apo vs. holo, Figure 2.8).  
 
36 
Table 2.1 Kinetic parameters for N-acetyl amino acid-stimulated ATP-PPi exchange 
reaction by MBP-PhsA-His6 in its apo and holo forms.  
Substrate 
Recom-
binant 
PhsA  
kcat 
(min-1) 
Km 
(µM) 
kcat / Km 
(µM-1 min-1) 
Endo-
genous 
enzyme30 
(±)-AcPT 
apoa 87.9 ± 2.9 26.9 ± 2.9 3.27 ± 0.37  
holob 83.5 ± 2.0 23.7 ± 1.9 3.52 ± 0.29 74% 
L-AcDMPT 
apo 122.9 ± 2.9 198 ± 18 0.62 ± 0.06  
holo 124.7 ± 6.5 254 ± 44 0.49 ± 0.09 100% 
N-AcGlu 
apo 25.0 ± 1.1 349 ± 55 0.0717 ± 0.011  
holo 28.8 ± 1.5 493 ± 82 0.0584 ± 0.010 11% 
          a The apo form of the enzyme was not treated with Sfp and CoA to install the phosphopantetheine arm.  
          b The holo form has been treated with Sfp and CoA as discussed in the text. 
 
2.2.5. Thiotemplate Analysis of Amino-Acid Loading on PhsA by FTMS 
The substrate specificity of holo-MBP-PhsA-His6 was further analyzed by 
competition experiments using FTMS in collaboration with Bradley S. Evans from the 
laboratory of Prof. Neil L. Kelleher (Department of Chemistry, UIUC). The protein (12.4 
μM) was incubated with a 1:1 mixture of AcDMPT and AcPT at 25, 250, and 450 μM of 
each amino acid in the presence of 1 mM ATP. After 1 h, the protein was analyzed by 
FTMS using the PPant ejection assay.49,50 The ions corresponding to PPant loaded with 
AcPT (466.1778) and AcDMPT (452.1616) were observed (Figure 2.10A) as well as the 
parent PPant ejection ion (261.1268). In two independent experiments, the ratios of the 
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peak intensities of AcPT-PPant and AcDMPT-PPant compounds favor the former at all 
three substrate concentrations. The presence of the parent ion51 (261.1267, data not 
shown here) and its unknown origin (holo PhsA, AcPT−PhsA, or Ac-DMPT−PhsA) 
complicate interpretation, but the FTMS experiments confirm that both substrates are not 
only adenylated but also loaded onto the T-domain. 
 
2.2.6. Role of Putative Thioesterase Motif in PhsA 
Instead of a typical Te domain at the C-terminus of NRPSs in the termination 
module (i.e. either PhsB or PhsC in PTT biosynthesis), a single thioesterase (Te) GXSXG 
motif is found in the N-terminus of PhsA (Figure 2.3C). In addition, two genes theA and 
theB were identified within the PTT biosynthetic gene cluster, and their gene products 
showed high similarity to type II thioesterases (TeII).27,35 Within polyketide and 
nonribosomal polypeptide biosyntheses, it has been shown that TeII enzymes may have 
editing roles.52,53 In order to analyze the thioesterase function of these genes, Schinko and 
coworkers have generated several mutants in the producing strain and showed that the 
thioesterase motif in the N-terminus of PhsA is required for PTT production. On the other 
hand, TheA and TheB might have editing functions as their knockout mutants only led to 
reduced PTT production.35  
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Figure 2.10 Competition loading results determined by the LC-FTMS PPant ejection 
assay at the indicated substrate concentrations. (A) Proposed structures of PPant ejection 
ions colored to match corresponding peaks. (B) Peak intensities of PPant ejection ions 
resulting from loaded AcPT and AcDMPT. These figures were prepared by Bradley 
Evans, and used with his permission. 
A 
B 
PhsA (WT) 
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If the Te motif in PhsA were to selectively remove AcDMPT (but not AcPT) after 
loading onto the PPant arm of the PCP domain, the higher ATP-PPi exchange activity of 
AcDMPT at high substrate concentration would not conflict with the lower amounts of 
loaded AcDMPT seen in Figure 2.10B. Two experiments were conducted to investigate 
the possible involvement of this Te motif in editing. First, the putative catalytic Ser1635 in 
the Te motif was mutated to Ala (MBP-PhsA-His6 S16A). The amino acid loading 
experiment described above was repeated with this mutant enzyme and the relative 
loading onto the T-domain was determined in a identical manner as was with the wild 
type PhsA. As shown in Figure 2.11, AcPT remained preferentially loaded at all substrate 
concentrations, suggesting the Te motif is not involved in any post-loading editing. In a 
second complementary experiment, potential time-dependent hydrolysis of thioester-
bound intermediates after loading was investigated with wild type MBP-PhsA-His6 and 
compared with the S16A mutant MBP-PhsA-His6. As shown in Figure 2.12, the ratio of 
AcDMPT to AcPT did not change much during a 1 h time course, suggesting that post-
loading editing also does not occur in S16A mutant MBP-PhsA-His6. 
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Figure 2.11 Peak intensities of PPant ejection ions resulting from loaded AcPT and 
AcDMPT in the assay with the MBP-PhsA(S16A)-His6 mutant protein.  
 
 
 
 
 
 
Figure 2.12 Relative peak intensities of AcDMPT to AcPT at 5, 10, 30 and 60 min after 
passage through a gel filtration spin column to remove small molecule substrates. WT 
MBP-PhsA-His6 ( ); MBP-PhsA-His6 S16A ( ). 
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2.3 – Discussion and Conclusion 
A high-level heterologous overexpression and purification system for PhsA was 
required in order to thoroughly study the first nonribosomal peptide synthetic step in PTT 
biosynthesis. This goal was accomplished using an MBP fusion protein, which resulted in 
a soluble enzyme with relative ATP-PPi exchange activity for three substrates (AcPT, 
AcDMPT, and AcGlu) comparable with that reported for the native enzyme isolated from 
S. viridochromogenes. The specific activity of the recombinant enzyme for the ATP-
pyrophosphate exchange activity under similar conditions is slightly (1.7-fold) higher 
than that of the native enzyme. The MBP tag could not be removed using Factor Xa 
without degradation of PhsA, suggesting that the protein is not very stable, consistent 
with the previous study on the native enzyme.30  
The much lower Km,app for AcPT compared to that for AcDMPT may indicate that 
this compound is the physiological substrate for PhsA, provided that free AcDMPT and 
AcPT are both biosynthetic intermediates (i.e. that the P-methyltransferase PhpK acts on 
AcDMPT in solution, vide infra). The preference for AcPT even at high substrate 
concentrations where AcDMPT is a better substrate for the PPi exchange reaction could 
be due to selective substrate loading with a preference for adenylated AcPT over 
adenylated AcDMPT, a fidelity filter not usually observed in NRPS systems.43,44 
Alternatively, the putative Te motif at the N-terminus of PhsA could have been involved 
in proofreading and catalyze selective hydrolysis of misloaded amino acids in a 
posttransfer editing step. However, in the test with the S16A mutant, the same selectivity 
was observed as for the wild-type enzyme, ruling out an editing role for the Te motif. 
Another possibility is that the MBP and His6 tags in the fusion protein influence the 
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activity of the protein. However, these tags do not appear to affect the amino acid 
dependent ATP-pyrophosphate exchange reaction since the observed activities are very 
similar to those of the native enzyme, and it seems unlikely (although possible) that 
loading onto the T-domain is selectively affected by the tags. 
Collectively, the observations in this study do not clarify the identity of the 
physiological substrate for PhsA and thus the timing of methylation on phosphorus. On 
one hand, a phsA disruption mutant accumulated AcDMPT, suggesting that this 
compound is the natural substrate.36,37 On the other hand, the results reported here 
suggest it may be AcPT. In support of the latter model, Seto and co-workers showed that 
a mutant producer strain accumulated AcPT and AcPT-Ala-Ala, suggesting free 
AcDMPT can be methylated by PhpK.34 Similarly, the cell-free extract of a Streptomyces 
lividans strain carrying a plasmid with a 9.5 kb fragment of the PTT biosynthetic gene 
cluster from S. hygroscopicus was able to carry out the methylation of both AcDMPT and 
AcDMPT-Ala-Ala.33 Of note, this DNA fragment carries the phpK and phsA genes but 
not the genes for PhsB and PhsC. Since AcDMPT-Ala-Ala is unlikely to be loaded onto 
PhsA, these results suggest the P-methyltransferase can act on free AcDMPT-Ala-Ala 
(free meaning not bound to an NRPS) and presumably also on free AcDMPT. This 
observation in turn would be consistent with AcPT being the substrate for PhsA. In this 
scenario, the observed accumulation of AcDMPT upon disruption of the phsA gene could 
be the result of disruption of protein-protein interaction. Such accumulation of a 
biosynthetic intermediate several steps upstream of a disrupted gene is not unprecedented 
in secondary metabolism. In summary, this study shows successful establishment of an 
overexpression system for PhsA in E. coli which opens the door for further investigations 
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of PhsA activity and bioengineering of PTT derivatives. On-going experiments in 
collaboration with the Nair group involve the structural analysis of PhsA which may 
provide a better understanding of substrate binding in the active site of PhsA. Finally, the 
results of this study lend support to the hypothesis that the biosynthesis of PTT involves 
P-methylation prior to peptide assembly.  
 
2.4 – Experimental Procedures 
2.4.1. Construction of pET15b-phsA, pMAL-c2x-phsA and pET28b-malE-phsA 
General Materials and Methods. All molecular biology techniques, including polymerase 
chain reaction (PCR), transformation and plasmid preparation, were performed using 
standard procedures.54 Restriction endonucleases, T4 DNA ligase, and polymerases were 
purchased from either New England Biolabs (Ipswich, MA) or Invitrogen (Carlsbad, 
CA). Failsafe PCR Premix buffers used in the GC-rich DNA PCR were purchased from 
Epicentre (Madison, WI). PCR amplifications were performed using an automated 
thermocycler (PTC 150, MJ Research). DNA fragments used in cloning experiments 
were isolated by gel purification using the Promega Wizard PCR cleanup kit (Madison, 
WI). Plasmid isolation was accomplished by Qiagen’s Midiprep or Miniprep kits 
(Valencia, CA). Chemically competent E. coli DH5α cells were purchased from the 
University of Illinois at Urbana-Champaign (UIUC) Cell Media Facility. Sequencing 
reactions were performed at the W.M. Keck Center for Biotechnology at the University 
of Illinois at Urbana-Champaign utilizing standard T7 forward and reverse primers (T7-
for/T7-rev). The PCR products were digested with the appropriate restriction 
endonucleases and then ligated into vector DNA that was digested with the same 
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restriction enzymes. Chemically competent E. coli DH5α cells were transformed with 
each ligation mixture and plated on Luria-Bertani (LB)-agar containing the appropriate 
antibiotic to select for positive clones. For pET15b and pMAL-c2x-based constructs, 
ampicillin (Sigma-Aldrich) was used at 100 μg/mL, and for pET28b-based constructs – 
kanamycin (Fisher) was used at 50 μg/mL concentration.  
 
pET15b-phsA [JHL-I-48-53, 59-62, 64, 77-80, 82-89]. The genomic DNA of S. 
viridochromogenes DSM 40736 was prepared in the laboratory of Professor William W. 
Metcalf (Department of Microbiology, UIUC). From this genomic DNA the phsA gene 
was amplified by PCR using a forward primer 5’-GGGAATTCCATATGACCGCAGCG 
ACACCGGACA–3’containing an NdeI restriction site (underlined) and a reverse primer 
5’-TATAAACGCGGATCCCTACGTCCCCTTCAGTTC–3’ containing a BamHI 
restriction site. Successful PCR products were digested with NdeI and BamHI and 
subsequently ligated into the double-digested pET15b vector (Novagen) with T4 DNA 
ligase.  
 
pMAL-c2x-phsA [JHL-II-45-79]. The phsA gene was amplified by PCR as described 
above using a forward primer 5’-GGAAGGATTTCAGAATTCATGACCGCAGCG-3’ 
containing an EcoRI site and a reverse primer 5’-TATAAACGCGGATCCCTACGTCCC 
CTTCAGTTC-3’ containing a BamHI site. The PCR product and pMAL-c2x vector were 
treated with the corresponding restriction enzymes and subjected to double ligation to 
produce a vector encoding PhsA fused at its N-terminus to maltose binding protein. 
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pET28b-malE-phsA [JHL-III-45-56, 58-64, 70-76]. The malE-phsA gene was amplified 
by PCR from the pMAL-c2x-phsA construct using a forward primer 5’-
GCCGCTCGCCCATGGCTATGAA AATCGAAGAAGGTAAACTGG-3’ and a reverse 
primer 5’-AGAGCGAAGAGCCTCGAGC GTCCCCTTCAGTTCGCG-3’ to introduce 
NcoI and XhoI restriction sites, respectively. The PCR product and pET28b vector were 
treated with these enzymes and then ligated to produce a vector encoding MBP-PhsA 
with a hexahistidine tag at its C-terminus. 
 
pET28b-malE-phsA (S16A) [JHL-VII-95-99, JHL-IX-11-20, 27]. The single point 
mutation encoding construct, pET28b-malE-phsA (S16A) mutant could not be prepared 
by a simple Quick-Change method, instead the “MegaWhop” method55 was used in 
which mega primers of more than 1.5 kb in length were used for whole plasmid PCR 
reaction. The mega primer was prepared by PCR from pET28b-malE-phsA wild type 
template using a forward primer 5’-CCGGACCGCACCGGCCCGGCCCCGGGGGCCT 
GCCCCGTC-3’ which introduces S16A mutant coding gene and a reverse primer 5’-
TGAGCGGCCTGGGCC-3’. DpnI was used to digest the methylated wild-type template. 
 
2.4.2. Expression and Purification of PhsA with Various Tags 
Expression of His6-PhsA [JHL-I-90-98, JHL-II-7-23, 32-38]. Electrocompetent E. coli 
BL21 (DE3) cells were prepared using standard methods.54 The cells were freshly 
transformed with pET15b-phsA. Single colony transformants were grown aerobically for 
12-15 h at 37 °C in 5 mL of LB medium supplemented with 100 µg/mL ampicillin. The 
fully grown cell culture was centrifuged at 5000×g for 15 min and the spent medium was 
46 
discarded. The pellet was carefully resuspended in fresh LB medium and the resuspended 
cells were used to inoculate a large-scale culture of 2-3 L of LB-ampicillin (100 µg/mL). 
The culture was grown with aeration at 37 °C until the optical density at 600 nm (OD600) 
reached 0.5-0.7. The expression of N-terminally His6-tagged PhsA was induced by 
addition of isopropyl-1-thio-β-D-galactoside (IPTG) from CalBiochem to a final 
concentration of 0.1 mM and the culture was continually shaken at 18 °C for an 
additional 12-15 h. After harvesting the cells at 5000×g for 15 min, the spent medium 
was discarded and the cell pellet was resuspended in buffer A (50 mM Tris, 300 mM 
NaCl, 15% glycerol (v/v), 10 mM β-mercaptoethanol, pH 7.8 at 4 °C) and lysed by 
incubation with lysozyme at a final concentration of 0.2 mg/mL for 30 min at RT before 
being analyzed for solubility of the expressed protein. 
 
Expression and Purification of MBP-PhsA [JHL-II-83-88, 91-92, JHL-III-6, 17, 23-24, 
26-41]. Electrocompetent E. coli BL21 (DE3) and Rosetta 2 (DE3) cells were prepared 
using standard methods,54 and used as expression hosts. Transformations of these strains 
with pMAL-c2x-phsA were carried out in a similar manner as described for the 
expression of His6-PhsA, except in the case of Rosetta 2 (DE3), a chloramphenicol (20 
µg/mL) marker was used in addition to ampicillin (100 µg/mL). The overnight starter 
culture was used to inoculate the 2 - 3 L of LB supplemented with the appropriate 
antibiotics as well as glucose (0.2% w/v final concentration) in order to repress 
expression of the maltose genes of the E. coli. The culture was grown at 37 °C until the 
optical density of A600 reached 0.5-0.7. The expression of PhsA as N-terminal MBP-
fusion was induced by addition of IPTG to a final concentration of 0.5 mM and the 
47 
culture was continued to grow at 18 °C for an additional 12-15 h. The cells were 
harvested at 5000×g for 15 min, the spent medium discarded, and the cell pellet 
resuspended in buffer A, supplemented with protease inhibitor cocktail tablets (Complete 
Mini, EDTA-free, Roche).  
Cell lysis was achieved by incubation of the cells in suspension buffer with 
lysozyme at a final concentration of 0.2 mg/mL for 30 min at RT followed by sonication 
(Sonics & Materials Inc. Vibra CellTM, 35% Amp, pulse sequence of 5.0 s on and 9.9 s 
off, 15 min) in an ice-water bath. The lysate was cleared by centrifugation (30 min, 
25,000×g), and passed through a 0.45 μm syringe filter (Corning) onto the amylose resin, 
which had been equilibrated with buffer B (20 mM Tris, 200 mM NaCl, pH 7.4 at 4 °C). 
After washing the protein-bound amylose resin with 8-10 column volumes of buffer B, 
the MBP-fusion protein was eluted from the column by elution with buffer C (20 mM 
Tris, 200 mM NaCl, 10 mM maltose, pH 7.4 at 4 °C). The elution fractions that contain 
the desired MBP-fusion protein as analyzed by SDS-PAGE (10% acrylamide gel in Tris-
glycine buffer) were combined and concentrated using a centrifugal filtering device 
(Ultra Amicon, Millipore, 30 kDa molecular weight cutoff). After excess NaCl and 
maltose were removed using a PD-10 desalting column (GE Healthcare) pre-packed with 
Sephadex G-25 medium, the protein was eluted with buffer D (20 mM Tris, 25 mM NaCl, 
pH 7.5). The purified MBP-PhsA was treated with Factor Xa protease to cleave MBP 
from the fusion protein (described below), and PhsA was separated from MPB by DEAE-
sepharose anion exchange chromatography with increasing NaCl concentration (from 25 
mM up to 500 mM) in the 20 mM Tris buffer. All purification steps were performed at 4 
°C. The protein concentration was determined using A280 measurement as well as 
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Bradford assay with Bovine Serum Albumin (BSA) as protein standard.  
 To improve protein folding and thereby reduce possible proteolytic degradation of 
MBP-PhsA during purification as well as during the Factor Xa cleavage reaction, 
chaperone proteins were co-expressed with MBP-PhsA in a commercially available host, 
BL21-pGKJE8 (Takara). After transformation of the strain by the method described 
above, a single colony was used to generate an overnight culture, which was then used to 
inoculate 3 L of LB-glucose medium supplemented with chloramphenicol (20 μg/mL) 
and ampicillin (50 μg/mL). The chaperone proteins, Dnak, DnaJ and GrpE were induced 
by L-arabinose (0.5 mg/mL, Aldrich), and GroEL and GroES were induced by 
tetracycline (5 ng/mL, Aldrich) both at the onset of the cell growth. When OD600 reached 
between 0.5 – 0.7, the cells were induced by addition of IPTG at a final concentration of 
0.5 mM. The culture was continued to grow at 37 °C for another 4 h or at 25 °C for 6 h, 
and harvested at 5000×g for 15 min. 
 
Expression and Purification of MBP-PhsA-His6 [JHL-III-68-69, 78-80, 84-85, JHL-IV-6, 
37, 53, JHL-V-10-11, JHL-VI-25, 87]. BL21-pGKJE8 strain was transformed with 
pET28b-malE-phsA, and following the procedure described above, the culture was grown 
at 37 °C in 3 L of LB medium supplemented with chloramphenicol (20 μg/mL) and 
kanamycin (50 μg/mL) as selection markers. Both L-arabinose (0.5 mg/mL) and 
tetracycline (5 ng/mL) were supplemented to induce the chaperone proteins. When the 
OD600 reached between 0.5 - 0.7, the cell culture was induced with (IPTG) to a final 
concentration of 0.1 mM, and continued to grow at 18 °C for an additional 12-15 h. The 
cells were harvested by centrifugation (15 min, 5000g), resuspended in buffer A with 
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protease inhibitor cocktail tablets (Complete Mini, EDTA-free, Roche), and disrupted by 
incubation with 0.2 mg/mL of lysozyme followed by sonication (pulse sequence of 5 s on 
and 9.9 s off, 15 min). The lysate was cleared by centrifugation (30 min, 30,000×g), and 
purified using Ni2+ affinity resin (Qiagen) equilibrated with buffer A containing 10 mM 
imidazole. The cell lysate was passed through a 45 µm filter before application to the 
resin. The column (1 x 10 cm) was washed with 20 column volumes of buffer A 
containing 25 mM imidazole. Elution of the desired His6-tagged protein was achieved 
using buffer A with increasing imidazole concentrations from 25 mM to 500 mM in 25 
mM increments (total volume = 200 mL), and the fractions containing the desired protein 
as determined by SDS-PAGE and Coomassie Blue staining were concentrated using 
Amicon Ultra with a 30 kDa membrane. Imidazole and NaCl were removed using a PD-
10 desalting column. The protein was eluted with buffer D, and was further purified on a 
HiTrap Q HP anion exchange column (GE Healthcare) pre-equilibrated with buffer B. 
Elution of the enzyme was carried out with buffer B in a step gradient of NaCl, from 25 
mM to 500 mM with 25 mM increments (total volume = 220 mL). The purified protein 
MBP-PhsA-His6 was concentrated using Amicon Ultra (30 kDa), mixed with glycerol to 
a final concentration of 20% (w/v), flash frozen in liquid nitrogen, and stored at -80 °C. 
Protein concentration was determined by Bradford assay using BSA as a protein standard. 
 
Factor Xa Cleavage of the MBP-fusion protein [JHL-II-94-95, JHL-III-6, 17, 34, JHL-
IV-12, 16]. Either MBP-PhsA or MBP-PhsA-His6 was incubated with Factor Xa (New 
England Biolabs) at 1% w/w (Factor Xa protease per total protein) in the elution buffer 
from the purification, typically for 3 h at either 4 °C or 25 °C.  
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2.4.3. In Vitro Phosphopantetheinylation of MBP-PhsA-His6 by Sfp 
General Materials. 3H-Acetyl coenzyme A ([3H]CoA) was purchased from MP 
Biomedicals, and radioactive tetrasodium 32P-pyrophosphate was purchased from Perkin 
Elmer. Both Sfp and BODIPY-CoA were prepared by the Kelleher group (Department of 
Chemistry, UIUC).  
 
Conversion of Apo-MBP-PhsA-His6 to Holo-MBP-PhsA-His6 [JHL-IV-10, JHL-V-61, 
JHL-VI-46-51]. For in vitro priming of MBP-PhsA-His6 to its holo form, 9.6 μM MBP-
PhsA-His6 was incubated with 25 μM CoA and 1 nmol Sfp for 1 h at 25 oC in assay 
buffer (50 mM HEPES pH 7.5, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 10 mM 
MgCl2) in a final volume of 150 µL.   
 
In-Gel Fluorescence Labeling Using BODIPY-CoA. MBP-PhsA-His6 was incubated with 
Sfp (4 μM) in a buffer containing 10 mM MgCl2, 2.4 mM DTT and 0.16 mM BODIPY-
CoA for 1-2 h at 30 °C. The reaction was quenched by adding an equal volume of SDS-
PAGE loading buffer. The reaction mixture was analyzed by running a 10% SDS-PAGE 
gel, exciting the fluorophore at 460 nm, and detecting at 520 nm. Subsequently, the gel 
was stained with Coomassie blue.  
 
Radioassay of the Phosphopantetheinylation Process [JHL-VI-55-59]. The activity of Sfp 
on MBP-PhsA-His6 was also monitored by measuring the incorporation of tritium-labeled 
acetyl CoA into apo-MBP-PhsA-His6 (13 μM) under the phosphopantetheinylation 
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conditions described above except for the use of [3H]CoA (20 mCi/mmol, 10 µCi/mL, 52 
µM) in place of CoA and the use of a lower Sfp concentration (0.1 µM). Reactions were 
initiated by addition of Sfp, and at each time-point, a 30 µL aliquot was taken from the 
reaction mixture, and quenched with 240 µL of 10% trichloroacetic acid (TCA). BSA 
(100 µg) was added as a carrier protein, and the precipitated protein was pelleted by 
centrifugation. After the supernatant was discarded, the pellet was washed three times 
with 240 µL of 10% TCA before resuspension in 100 µL formic acid. Liquid scintillation 
cocktail (ScientiSafe Econo 1, Fisher Scientific) was added to the protein suspension, and 
the radioactivity of tritium bound to the protein was quantified by liquid scintillation 
counting.  
 
2.4.4. Determination of Substrate Specificities 
Kinetic Analysis of the Pyrophosphate Exchange Reaction [JHL-IV-19-24, 42, 56-60, 85-
98, JHL-V-15-17, 27-32, 40, 44-52, 64, JHL-VI-21-22, 46-51]. The reactions were 
carried out in 90 µL total volume containing 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 
mM DTT, 2 mM Na4PPi, 1 µCi [32P]PPi, 0.005 - 4 mM of substrate and 0.52 µM of holo 
MBP-PhsA-His6. The reaction mixture was equilibrated at 30 °C before initiation of the 
reaction with addition of 2 mM ATP. Aliquots were taken at each time-point, and 
analyzed by thin layer chromatography (TLC) using polyethyleneimine plates (Scientific 
Adsorbents Inc., Atlanta, GA) pre-run in water. ATP and pyrophosphate were resolved 
using a developing solvent of 750 mM KH2PO4, pH 3.5, and 4 M urea. Separated 
radiolabeled products were visualized using a phosphorimaging plate (Fujifilm, BAS-
MS2040), and the scanned image (StormTM) was analyzed using ImageQuant software. In 
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addition to the expected exchange of 32P from pyrophosphate into ATP, small amounts of 
radiolabeled ADP and trace amounts of Pi were also observed, as has been seen in other 
studies of adenylation domains.56 ADP is typically not identified using the charcoal 
adsorption method as both ATP and ADP are adsorbed to the charcoal. The formation of 
these additional products was dependent on both PhsA and substrate. Inclusion of these 
radiolabeled products resulted in the same trends (larger apparent kcat for AcDMPT, 
smaller apparent Km for AcPT) as did omitting them from the analysis. For apo-MBP-
PhsA-His6, the protein was treated under the same conditions as for holo protein.  
 
FTMS Analysis of MBP-PhsA-His6 after Loading with AcPT and AcDMPT [JHL-VI-75, 
JHL-VII-10]. Samples for FTMS were prepared in the same manner as in the 
pyrophosphate exchange assay except that higher concentrations of protein were utilized. 
A solution of 46.5 μM MBP-PhsA-His6 in 70 mM Tris-HCl, 10 mM MgCl2, 2 mM DTT, 
4 μM Sfp, and 200 μM CoA was incubated at 30 oC for 30 min for 
phosphopantetheinylation. To the solution was then added ATP (10 mM final 
concentration) and 25, 250 or 450 μM AcDMPT or AcPT (final concentrations) and the 
assays were incubated for 1 h at 30 oC followed by quenching with 5% formic acid, 
centrifugation to remove any particulates, and analysis by LC-MS. All mass spectral data 
were collected by Bradley S. Evans (Kelleher group) on a 7 Tesla LTQ-FT (Thermo 
Fisher Scientific) equipped with a Surveyor MS pump and autosampler. Reverse phase 
liquid chromatography (RPLC) was carried out on a Jupiter 2.0 X 50 mm C4 column 
(Phenomenex) using water (solvent A) and acetonitrile (solvent B) with 0.1% formic acid. 
LC-MS assays used a gradient program starting at 30% B increasing to 65% B over 15 
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min followed by a 20 min re-equilibration to initial conditions. The mass spectrometric 
method consisted of a low resolution ion trap full MS scan followed by a pseudo-MS2 
scan (NS at 75 V) for the phosphopantetheine (PPant) ejection assay. Note that all species 
entering the mass spectrometer are fragmented simultaneously giving rise to highly 
complicated MS/MS data; however, the <5 part-per-million mass accuracy is the key to 
monitoring the specific m/z channels corresponding to the ions from PPant ejection. LC-
MS data was analyzed using QualBrowser software (Thermo Fisher). For quantitation of 
PPant ejection products, Nozzle-Skimmer dissociation (NS) scans were summed over the 
period of MBP-PhsA-His6 elution for each LC-MS run to obtain the total normalized 
levels of the PPant ejection ions. The predominant product was set to 100% and the 
substrate with lower activity was normalized to that value. Results from five replicate 
assays were used for comparison, with an observed precision of 9.7, 7.3 and 4.1% at 1 
sigma for the 25, 250 and 450 μM assays, respectively.  
 
2.4.5. Synthesis of Substrate Analogues 
General Materials and Methods. All NMR spectra were recorded on Varian U400 or 
Varian U500 spectrometers. 1H NMR spectra were referenced to TMS at 0 ppm or CHCl3 
at 7.26 ppm, and 13C NMR spectra were referenced to CDCl3 at 77.7 ppm. Mass 
spectrometry (MS) experiments were carried out by the Mass Spectrometry Laboratory at 
the University of Illinois at Urbana-Champaign. Fractions collected during silica gel 
column chromatography were analyzed by TLC. Unless otherwise specified, all 
compounds and solvents were obtained from Fisher or Aldrich. THF was distilled over 
sodium/benzophenone, and CH2Cl2 was distilled over CaH2 prior to use. AcDMPT was 
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synthesized and characterized as described in the Supporting Information of Reference 
(31). L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4) was purchased from Tocris 
Bioscience. Both L-Glu and L-Asp were purchased from Sigma-Aldrich, and PT was 
obtained from Matrix Scientific. These acids were acetylated with acetic anhydride in the 
presence of potassium carbonate in water [JHL-III-91-93, JHL-IV-13-15]. Substrate 
concentrations in stock solutions were determined by integration of the corresponding 
phosphorus peak area in the 31P NMR spectra.  
 
2-Aminobutyrolactone hydrobromide (1) [JHL-I-4-6, 8, 27, 37].57 To a 100 mL round-
bottomed flask containing L-methionine (2.14 g, 14.3 mmol) was added 10 mL of H2O, 
10 mL of isopropyl alcohol, and 4 mL of glacial acetic acid. To this suspension was 
added bromoacetic acid (18.64 mmol) and the reaction was stirred under N2 at 50 °C until 
all solids had dissolved. The solution was then refluxed at 100-110 °C for 6 h. The 
solvent was removed under reduced pressure using a rotary evaporator and the resulting 
oil was redissolved in 1.5 mL of 1:1 of isopropyl alcohol/toluene. The suspension was 
concentrated under reduced pressure to remove remaining H2O giving a yellow emulsion. 
To this, 9 mL of 4 M HCl in dioxane was added, stirred at room temperature for 20 min, 
and the reaction was placed at 4 °C overnight. The solid was filtered and washed with 
cold dioxane to produce 1.9 g of pinkish solid product (73-81%), m.p. 221–224 °C (lit. 
234–236 °C).21  1H NMR (500 MHz, D2O)  δ 4.45 (t, 1H); 4.32-4.28 (m, 2H);  2.67-2.61 
(m, 1H); 2.28 (q, 1H), 13C NMR (500 MHz, D2O) δ 174.67, 67.44, 48.61, 26.85. 
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Aminobromobutyrate hydrobromide (2) [JHL-I-7, 17, 28, 65]. A high pressure glass tube 
was charged with 2 g of compound 1 and 11 mL of 33% HBr/HOAc. The suspension was 
stirred at 35 ˚C for 30 min, and then the temperature was raised to 75 ˚C. After 20 h, a 
white solid of bromide was obtained, which was filtered and washed with cold ether to 
yield white product as a solid (94%), m.p. 181-183 °C (lit 187-188 °C).37 1H NMR (500 
MHz, D2O) δ 4.09 (t, 1H); 3.45 (m, 2H); 2.45-2.22 (m, 2H). 
 
Aminobromomethyl butanoate (3) [JHL-I-9, 18, 29, 66]. Acetyl chloride (14 mL, 10 
equiv.) was added dropwise to anhydrous MeOH (100 mL) at 0 ˚C. Upon completion of 
addition, the mixture was allowed to warm to room temperature and was stirred for 30 
min before 5.4 g of compound 2 (20.5 mmol) was added. The mixture was then stirred 
for another 20 h. The solvent was removed under reduced pressure to afford methyl ester 
as yellow oil in a quantitative yield. 1H NMR (500 MHz, D2O) δ 4.18 (t, 1H); 3.68 (s, 
3H); 3.45 (m, 2H); 2.45-2.22 (m, 2H). 31C NMR is as reported in the literature.37 
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CHAPTER 3: ELUCIDATING THE BIOSYNTHETIC PATHWAY OF 
DEHYDROPHOS USING BIOCHEMICAL APPROACHES* 
 
3.1 – Introduction 
Dehydrophos, originally designated A53868, is a broad-spectrum antibiotic 
produced by Streptomyces luridus.1 It was first discovered by Eli Lilly and Company in 
1984, and has been shown to inhibit the growth of Gram-negative and Gram-positive 
bacteria and demonstrated in vivo activity against Salmonella.1 The chemical structure of 
dehydrophos has been revised several times2 until finally the correct structure was 
confirmed using NMR spectroscopic data and comparison to an authentic synthetic 
compound.3 The revised structure of dehydrophos contains a unique O-methyl 
aminovinylphosphonate ester that is attached to the C-terminus of a Gly-L-Leu dipeptide 
(Figure 3.1).3 Due to the structural similarity to dehydroalanine, the compound was 
renamed as dehydrophos. As is commonly observed in other oligopeptide phosphonate 
antibiotics,4 dehydrophos is thought to be taken up by target organisms via non-specific 
oligopeptide permeases.5,6 Once inside the cell, the peptide is likely hydrolyzed by 
peptidases to release the active phosphonate-containing part of the compound.  
The important properties of C-P compounds and the common strategies found in 
the biosynthesis of these compounds were discussed in Chapter 1. The molecular target 
of dehydrophos is currently not known. Nonetheless, the free phosphonate released from 
dehydrophos after its hydrolysis by peptidase(s) is projected to be methyl 
acetylphosphonate (Figure 3.1),7 which can potently inhibit pyruvate dehydrogenase 
                                                 
*
 Reproduced in part with permission from “Molecular Cloning and Heterologous Expression of the 
Dehydrophos Biosynthetic Gene Cluster” Chem. Biol. 2010, 17, 402-411. Copyright 2010 by Elsevier Ltd.  
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activity,8 a crucial enzyme reaction in bacterial metabolism. Alternatively, the reactive 
vinyl moiety of the tripeptide could inhibit a cellular process directly, as is found in the 
phosphonopeptide K-26, where hydrolysis of peptide bond is not necessary for biological 
activity.9 Another interesting aspect of the dehydrophos structure is the methylation of 
the phosphonate group. The rationale for installation of the methyl group may be the 
enhancement of bioavailability of dehydrophos by reducing its charge state in the ester 
form. Alternatively, the methyl ester may enhance interaction with the target of 
dehydrophos. In fact, it has been reported that methyl acetylphosphonate inhibits 
pyruvate dehydrogenase over 100-fold more potently than the unesterified 
acetylphosphonate.8 The methylation reaction of the phosphonic acid group during 
dehydrophos biosynthesis will be discussed in depth in Chapter 4.  
 
 
 
Figure 3.1 The confirmed chemical structure of dehydrophos. The compound is made of 
a tripeptide, Gly-L-Leu-vinylaminophosphonate. The product of dehydrophos proteolysis, 
methyl acetylphosphonate, is thought to be a structural mimic of pyruvate and a possible 
inhibitor of pyruvate dehydrogenase.  
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The dehydrophos biosynthetic gene cluster has been identified and cloned in the 
laboratory of Prof. William W. Metcalf (Department of Microbiology, UIUC) using the 
phosphonate discovery method outlined in Chapter 1.7 Briefly, a fosmid library of S. 
luridus was screened for the gene encoding phosphoenolpyruvate (PEP) mutase 
catalyzing the first enzymatic step in most known phosphonate biosynthetic pathways 
(Figure 1.3). After sequencing the PEP mutase-positive clones and subsequent gene 
deletion experiments, the minimal contiguous gene cluster responsible for dehydrophos 
production was identified. The fosmid containing the putative dehydrophos gene cluster 
was integrated into S. lividans, which allowed for heterologous production of 
dehydrophos.7 Bioinformatics analysis identified 16 open reading frames (ORFs), dhpA-
dhpP (Figure 3.2) within the gene cluster for which protein functions could be proposed 
by sequence homology to enzymes of known functions. Based on this analysis, a 
hypothetical biosynthetic pathway for dehydrophos has been proposed (Figure 3.3).7 
The first two steps resemble the transformations found in other known 
phosphonate biosynthetic pathways. First, PEP is isomerized to phosphonopyruvate 
(PnPy) by the action of PEP phosphomutase DhpE, a reaction thermodynamically 
unfavorable, yet when coupled with subsequent DhpF-catalyzed PnPy decarboxylation 
ultimately results in the formation of phosphonoacetaldehyde (PnAA). Fe-dependent 
dehydrogenase DhpG converts PnAA to 2-hydroxyethylphosphonate (2-HEP).10 As such, 
the first three steps of the dehydrophos pathway are similar to those found in the 
biosynthetic pathways of PTT and fosfomycin.10,11 The early part of the remainder of the 
proposed biosynthetic steps as well as the later methyl transfer step of the dehydrophos 
pathway have been validated by analysis of intermediates accumulated by gene-blocked 
63 
mutants or by in vitro reconstitution of the enzyme activities. This chapter describes 
elucidation of the remaining steps of dehydrophos biosynthesis. The gene knockout 
mutants were prepared and their metabolite production was analyzed by Benjamin T. 
Circello from the Metcalf laboratory. In order to identify the produced metabolites, 
synthetic standards were prepared in my work and employed as described below. 
Biochemical approaches were utilized where in vitro enzymatic activity provided the 
substrate scope of the reactions using synthetic substrates and products and their 
analogues. Most of the phosphonate compounds required for the identification of 
unknown compounds in NMR or mass spectroscopic (MS) analysis as biosynthetic 
intermediates in genetic approaches, or substrate and product analogues in biochemical 
approaches as well as for their use as standards for quantification in MS were not 
commercially available and were prepared in this work by chemical synthesis. Based on 
results obtained from these two different approaches, which are often complementary to 
one another, each step in the proposed hypothetical biosynthetic pathway were confirmed 
or strongly supported.  
Understanding the biosynthesis of phosphonates such as dehydrophos is important 
in learning the strategies Nature employs for production of novel phosphonates. As well, 
the biochemistry behind chemically unprecedented transformations of dehydrophos can 
provide valuable information. For instance, how the two important steps, namely 
installation of the vinyl group and the tripeptide formation, are achieved in dehydrophos 
biosynthesis is not clear at this stage. Neither a dehydratase enzyme, which often takes 
part in vinyl moiety formation, nor peptide-forming enzymes such as nonribosomal 
peptide synthetases or ATP-grasp enzymes are present in the gene cluster. Therefore, 
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alternative methods are likely used for these transformations in the dehydrophos-
producing strain. Uncovering theses unknown reactions will provide valuable insight in 
how these transformations, seemingly unique to dehydrophos, are taking place. 
Furthermore, learning what strategy Nature has adopted to produce novel phosphonates 
enables further downstream engineering of these biologically active compounds to 
contain better pharmacokinetic properties towards medicinal applications.  
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Figure 3.3 Proposed biosynthetic pathway of dehydrophos. Biosynthetic steps that have 
been confirmed in this work either genetically7 or biochemically are represented in solid 
arrows and proposed steps are shown in dashed arrows. 
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3.2 – Results 
3.2.1. Conversion of 2-HEP to 1,2-DHEP by DhpA 
Based on the amino acid sequence homology to dioxygenases, DhpA was 
proposed to catalyze the conversion of the known intermediate 2-HEP to 1,2-
dihydroxyethylphosphonate (1,2-DHEP) (Figure 3.3). In order to verify the conversion 
by DhpA, a phosphonate compound, which accumulated in the spent medium of a dhpA-
blocked mutant (∆DhpA) generated by B. Circello, was analyzed by 31P NMR 
spectroscopy.7  
31P NMR spectroscopy is a valuable tool in identification of phosphonate 
compounds whose chemical shifts are within a specific range of 5-30 ppm, well distant 
from those of the more predominant phosphates and phosphate esters that usually appear 
in a region more upfield (-20 to 5 ppm). It should be noted, however, that care should be 
taken when analyzing phosphonate compounds as the phosphorus chemical shifts can 
vary substantially (up to 5 ppm difference observed) depending on several factors such as 
pH and ionic strength of the sample. To conclusively verify the identity of a phosphonate, 
the sample of the unknown phosphonate needs to be mixed with an authentic standard 
and analyzed under the same 31P NMR condition. A single peak is indicative of the 
unknown compound being the same molecule as the authentic sample supplemented, 
whereas appearance of a new peak suggests they are two different molecular species, 
provided there is no degradation of the phosphonate subjected to the NMR analysis. 
The intermediate 2-HEP (Figure 3.3) was prepared from commercially available 
dimethyl 2-HEP ester (1) by facile bromotrimethylsilane-catalyzed hydrolysis in 
quantitative yield (Scheme 3.1). The 31P NMR spectrum of 2-HEP displayed a peak with 
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a chemical shift of 19 ppm, similar to that of the unknown compound that accumulated 
by the ∆DhpA mutant. When synthetic 2-HEP was added to the spent media of the 
∆DhpA mutant, no new phosphonate peak was observed in the 31P NMR spectrum. 
Therefore, it was confirmed that the unknown phosphonate produced by ∆DhpA is 
indeed 2-HEP.  
DhpA activity was also analyzed in an in vitro enzymatic assay by B. Circello 
using heterologously produced protein. When 2-HEP was incubated with DhpA in a 
buffered solution containing α-ketoglutarate, formation of a new phosphonate with a 
chemical shift at 16 ppm in the 31P NMR spectrum was observed. The dimethyl ester of 
the anticipated product and putative pathway intermediate 1,2-DHEP was prepared by 
Sharpless asymmetric dihydroxylation of vinyl phosphonate dimethyl ester utilizing 
osmium tetraoxide and chiral ligands (DHQD)2PHAL and (DHQ)2PHAL (Scheme 3.2). 
Dimethyl ester (2) produced in this manner was subsequently hydrolyzed to the 
corresponding acid (3) using bromotrimethylsilane in a quantitative yield (Scheme 3.2). 
Enantiomerically enriched 1,2-DHEP was prepared with the purpose of utilization of 1,2-
DHEP as a putative substrate in the subsequent enzymatic reactions, where the chirality 
of the substrate is important. However, since 31P NMR spectroscopy does not 
differentiate between the two enantiomers it was not necessary to determine the 
enantiomeric excess of the synthetic product for the experiments described in this chapter. 
Synthetic product was used in 31P NMR experiments as described above to confirm that 
the product of the DhpA reaction was indeed 1,2-DHEP.  
The possibility of 2-HEP being the substrate for the methyltransferase to be 
transformed into 2-HEP-OMe prior to the oxygenation to 1,2-DHEP-OMe could not be 
69 
ruled out. Therefore, synthesis of putative substrate and product in this alternative 
scenario, 2-HEP-OMe (4) and 1,2-DHEP-OMe (5) respectively, were carried out. In 
order to remove just one of the methyl ester groups, the corresponding dimethyl ester was 
refluxed in 10% aqueous sodium hydroxide solution until the starting material was 
completely consumed. This reaction resulted in a quantitative conversion of the dimethyl 
phosphonate ester to monomethyl phosphonate ester in a facile manner (Scheme 3.2). In 
case of monodeprotection of dimethyl 1,2-DHEP ester (2) to 1,2-DHEP-OMe (5), the 
dihydroxyl group was first masked as an acetonide using acetone in the presence of p-
toluenesulfonic acid to efficiently isolate the otherwise water-soluble product from the 
aqueous solvent. Refluxing the acetonide in 10% aqueous sodium hydroxide solution 
afforded deprotection of the acetonide and cleavage of one of the methyl groups in the 
dimethyl ester. 
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Scheme 3.1 Synthesis of 2-HEP (1) and 2-HEP-OMe (4). 
 
 
 
 
Scheme 3.2 Synthesis of 1,2-DHEP (3) and 1,2-DHEP-OMe (5). 
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3.2.2. Conversion of 1,2-DHEP to1,2-DHEP-OPO32- by DhpB 
 Initially, it was speculated that the formation of 1,2-DHEP was followed by its 
oxidation to 1-oxo-2-hydroxyethyl phosphonate (1-oxo-2-HEP) (Figure 3.4) catalyzed by 
DhpC (a homolog of malate/lactate dehydrogenases). Such transformation would be very 
similar to the malate-oxaloacetate interconversion catalyzed by malate dehydrogenase. 
As such, the gene deletion mutant for ∆DhpC was expected to accumulate a putative 
DhpC substrate, 1,2-DHEP. The ∆DhpC mutant generated by B. Circello produced two 
phosphonate intermediates with 31P NMR peaks at approximately 15 ppm, one of which 
was shown to be 1,2-DHEP using the synthetic standard. Accompanied by these two 
peaks were the peaks resulted from the upstream intermediates 2-HEP and 2-AEP and 
phosphate groups. The presence of another phosphonate in this experiment suggests that 
DhpC may not catalyze the immediate step following DhpA, but another reaction or 
reactions may occur prior to the DhpC-catalyzed step in the biosynthesis of dehydrophos. 
Unfortunately, attempts to prepare 1-oxo-2-HEP via synthetic methods described below 
(Scheme 3.3) were not successful to provide clear evidence of the presence of 1-oxo-2-
HEP in the DhpC catalyzed reaction utilizing 1,2-DHEP as substrate. However, when 
DhpC culture supernatant was treated with alkaline phosphatases in B. Circello’s 
experiment, 1,2-DHEP resulted suggesting the other phosphonate produced by ∆DhpC is 
1,2-DHEP phosphate ester. 
  In my attempts to obtain 1-oxo-2-HEP, glycolic acid was protected with tert-
butyldimethylsilyl (TBDMS) chloride in the presence of imidazole followed by 
conversion to the acyl chloride by oxalyl chloride. This chloride was subjected to 
Arbuzov-type addition of phosphite12 but the desired product could not be obtained. 
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Similarly, benzyloxyacetyl chloride was directly subjected to an Arbuzov-type phosphite 
addition reaction followed by the cleavage of the benzyl ether and methyl esters but the 
desired product could not be obtained. According to the 1H NMR a peak with a large 
coupling constant was observed suggesting the presence of a hydrogen phosphonate 
species in the product mixture. 
 
 
 
 
 
 
Figure 3.4 Retrosynthesis outlining series of enzymatic reactions leading to desmethyl 
dehydrophos starting from 2-HEP. 
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Scheme 3.3 Attempted synthetic routes to 1-oxo-2-HEP.  
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The protein product of dhpB is homologous to glycerate kinases, and it can be 
perceived that this enzyme takes 1,2-DHEP as a substrate to phosphorylate the hydroxyl 
group at the C2 position. The ∆DhpB mutant indeed produced 1,2-DHEP in a gene-
blocked mutant experiment performed by B. Circello.7 My attempt to express DhpB with 
an N-terminal hexahistidine tag from a heterologous host was not successful resulting in 
poor expression. Moreover, the small amounts of DhpB overexpressed (confirmed by 
Western Blot with anti-His6) at an optimized induction condition produced insoluble 
protein. Coexpression with chaperone proteins such as DnaK, DnaJ and GrpE using a 
commercially available chaperone plasmid, pG-KJE8 or employing the betaine-sorbitol 
osmotic stress system, which often improves protein solubility, did not improve the 
solubility of DhpB. Finally, a DhpB construct in which the protein was fused to the 
maltose binding protein (MBP) at its N-terminus was prepared, but soluble protein could 
not be obtained. Alternative attempts towards in vitro reconstitution of DhpB, which may 
support the hypothesis of 1,2-DHEP being the physiological substrate and its phosphate 
ester the product, are still under investigation.  
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3.2.3. Production of 1-HEP-OMe, an Unexpected Metabolite 
During the gene-knockout experiments carried out by B. Circello, an unknown 
compound with a peak at 24.5 ppm by 31P NMR was observed from the growth media of 
two different strains. One was a mutant strain ∆DhpK, and the other one was a lacI 
repressor-deleted mutant strain. Synthetically available phosphonate intermediates 
proposed to form during the biosynthesis were used as authentic standards in the 31P 
NMR method described previously, but none of these compounds matched the unknown 
at 24.5 ppm. The unknown phosphonate compound in the spent growth media could also 
not be isolated efficiently for further analysis. Instead, I carried out a 2-dimensional 1H-
31P Heteronuclear Multiple Bond Correlation (HMBC) NMR experiment to obtain 
information on the types of protons that are near to phosphorus.  
1H-31P HMBC NMR of the intermediate is shown in Figure 3.5. which was used 
to identify the chemical shifts of protons coupled to the 31P nucleus (i.e. less than 4 bonds 
away). This technique is selective and relieves overlap by proton peaks arising from 
solvent, nutrients, and other non-phosphonate metabolites. Only three proton peaks which 
were coupled to the phosphorus peak at 24.5 ppm were observed (Figure 3.5A). In the far 
upfield region, a doublet of a medium height at 1.3 ppm was observed in addition to a 
strong peak at 3.6 ppm and a small peak at 3.9 ppm. The strength of the signal can be a 
result of the combination of the number of bonds separating the nuclei as well as the 
number of protons contributing to the peak. Using the known chemical shifts of protons 
in the ethylphosphonate backbone with putative functional groups installed at various 
positions, several chemical structures including 1-HEP-OMe were proposed as a structure 
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of the unknown compound. 1-HEP-OMe would also explain the complex 31P NMR 
spectrum. 
In order to verify this hypothesis, 1-HEP-OMe was synthesized (Scheme 3.4). 
Condensation of acetaldehyde and dimethyl phosphite produced 1-HEP dimethyl ester, 
which was subsequently treated with iodotrimethylsilane or sodium hydroxide solution to 
afford 1-HEP and 1-HEP-OMe, respectively, both in quantitative yield. The 1H-31P 
HMBC NMR for 1-HEP-OMe was taken (Figure 3.5B). The spectrum matched well with 
the spectrum of the sample of the intermediate produced by the ∆DhpK mutant (Figure 
3.5A), and when the two samples were mixed and analyzed by 31P NMR spectroscopy, 
only one phosphorus peak at 24.5 ppm could be observed showing the identity of the 
unknown to be 1-HEP-OMe. Based on the observation that dehydrophos readily breaks 
down into acetyl phosphonate monomethyl ester and a dipeptide by cellular peptidase 
hydrolysis, it was proposed that 1-HEP-OMe is a metabolite generated by an endogenous 
lactate dehydrogenase activity on acetyl phosphonate monomethyl ester (Figure 3.5). 
Using acetyl phosphonate monomethyl ester and 1-HEP-OMe which were synthesized by 
myself according to the literature procedure,8 Ben Circello was able to show that the 
dehydrophos indeed generated 1-HEP-OMe after incubation in S. lividans cell culture 
media. 
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Scheme 3.4 Synthesis of 1-HEP and 1-HEP-OMe. 
 
 
 
 
  
 
Figure 3.5 A proposed route to the formation of 1-HEP-OMe. 
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Figure 3.6 2-Dimensional 1H-31P HMBC NMR. (A) A spectrum taken from a sample of 
concentrated spent medium in which ∆DhpK was grown and (B) a spectrum of an 
authentic synthetic 1-HEP-OMe sample. 
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3.3 – Discussion and Conclusion 
 As part of a multidisciplinary project investigating naturally occurring 
phosphonates with biological activity, this chapter describes a successful application of 
using the PEP mutase gene as a phosphonate marker for identifying and isolating a 
phosphonate gene cluster. Both genetic and biochemical approaches were applied in the 
elucidation of the dehydrophos biosynthetic pathway outlined in this chapter. The early 
steps in the dehydrophos biosynthesis are shared by biosynthetic steps of other 
phosphonates including fosfomycin and PTT. Due to the high homology of DhpE and 
DhpF to the corresponding PEP mutase and PnPy decarboxylase involved in the first two 
transformations of most known phosphonate compounds, their roles were assigned to be 
PEP mutase-catalyzed conversion of PEP to PnPy and the subsequent decarboxylation to 
PnAA. Similarly DhpG was assigned a function of Fe-dependent alcohol dehydrogenase 
as often observed in other phosphonate biosynthesis, which catalyze conversion of PnAA 
to 2-HEP.10    
 Based on the structure of dehydrophos, protein functions predicted from their 
amino acid sequence using NCBI’s BLAST search, and the chemical logic starting from 
2-HEP, a biosynthetic pathway for dehydrophos was proposed. Using this proposed 
pathway and putative substrate and product in each step, genetic and biochemical 
analysis was performed. In the genetic approaches conducted by B. Circello, phosphonate 
compounds produced by gene-blocked mutants were analyzed using 31P NMR without 
purification, and their identity was determined by comparison with authentic synthetic 
compounds available via synthesis. When the compounds could not be identified in this 
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manner, 1H-31P HMBC NMR was used to obtain information on the chemical structure of 
the unknown compound.  
 Several phosphonate compounds such as 2-HEP, 2-HEP-OMe, 1,2-HEP, 1,2-
HEP-OMe, 1-HEP, 1-HEP-OMe, acetyl phosphonate, and acetyl phosphonate-OMe used 
in this study were prepared successfully by chemical synthesis. Not only have these 
compounds served as synthetic standards in elucidating the dehydrophos biosynthetic 
pathway, but these compounds also make up a phosphonate library with applications in 
biosynthetic studies of other important phosphonates. This study demonstrates that DhpA 
converts 2-HEP to 1,2-DHEP by DhpA-catalyzed oxygenation as supported by both gene 
deletion and reconstitution of heterologously expressed DhpA using 2-HEP as substrate 
in the presence of α-ketoglutarate. Although activity of DhpB could not be reconstituted 
in vitro, the gene deletion experiment of DhpB, which resulted in accumulation of 1,2-
DHEP, as well as the gene deletion study of DhpC, which showed production of a 
phosphate ester of 1,2-DHEP, suggests the step following DhpA is DhpB-catalyzed 
phosphorylation of the 2-hydroxyl group in a similar reaction to glycerate kinases. While 
biochemical evidence is still to be obtained, the next step is suspected to be catalyzed by 
malate dehydrogenase, DhpC, which may convert 1,2-DHEP-OPO32- to 1-oxo-2-HEP- 
OPO32-.  
 While the remaining steps are yet to be elucidated, this study was able to provide 
a synthetic, biochemical, and genetic approach to discovery of novel enzymatic 
transformations as well as new phosphonate intermediates. Having the knowledge of 
phosphonate biochemistry in hand, further engineering of these unidentified 
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phosphonates may provide a reservoir for new compounds with useful biological 
activities. 
 
3.4 – Experimental Procedures 
3.4.1. Chemical Syntheses of Phosphonates 
General Materials and Methods for Chemical Synthesis. All NMR spectra were recorded 
on a Varian Unity 400 or a Varian Unity 500 spectrometer. 1H NMR spectra were 
referenced to TMS at 0 ppm or H2O at 4.67 ppm, and 13C NMR spectra were referenced 
to CHCl3 at 77.0 ppm. For 31P NMR spectra 85% phosphoric acid in D2O was used as an 
external reference (0 ppm). Fractions collected during silica gel column chromatography 
were analyzed using thin layer chromatography (TLC). Unless otherwise specified, all 
compounds and solvents were obtained from Fisher Scientific or Sigma-Aldrich. CH2Cl2 
was distilled over CaH2 immediately prior to use. 
 
Dehydrophos. Dehydrophos was synthesized and purified according to a literature 
procedure3 and utilized within a month after its preparation due to its decomposition 
overtime. 
  
2-Hydroxyethylphosphonate methyl ester (4). To an aqueous solution of 10% sodium 
hydroxide (10 mL) was added dimethyl 2-hydroxyethylphosphonate dimethyl ester (4) 
(6.49 mmol), and the reaction was refluxed for 1 h. After cooling to room temperature, 
the reaction mixture was acidified with 2 M HCl, concentrated, and redissolved in 20 mL 
of methanol. The suspension was passed through a plug of celite to afford the desired 
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product in a quantitative yield.  1H NMR (400 MHz, CDCl3) δ 3.70 (2H, dt, J = 14.4, 7.2 
Hz, CH2OH), 3.35 (3H, d, J = 11.2 Hz, OCH3), 2.01 (2H, dt, J = 18.4, 7.2 Hz, PCH2); 13C 
NMR (125.6 MHz, D2O) δ 56.4 (HOCH2), 51.8 (OCH3, d, J = 5.5 Hz), 28.6 (CH2P, d, J 
= 132.5 Hz); 31P NMR (202.3 MHz) δ 28.6. HRMS (EI) calcd for C3H9O4P 140.0239 
found 140.0228. 
 
1,2-Dihydroxyethylphosphonate dimethyl ester (2).13 To a suspension of AD mix β* 
(6.02 g) in 50 mL of 1:1 tert-butanol/H2O, which had been stirred for 15 min at room 
temperature, was added dropwise dimethyl vinylphosphonate (4.3 mmol, Alfa Aesar) and 
the solution was stirred for 4 days at room temperature. The yellow suspension was 
placed in an ice bath and quenched by the addition of sodium sulfite (5.0 g) upon which 
the solution turned green. After 20 min the ice bath was removed, and the suspension was 
stirred at room temperature for another 20 min. The solution was extracted with ethyl 
acetate (3 × 50 mL), and the combined organic layer was dried over magnesium sulfate. 
After evaporating the excess solvents and reagents, the crude product was purified by 
silica gel column chromatography (EtOAc:MeOH = 4:1, Rf=0.4) to afford the desired 
product in 29% yield as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 4.13-4.10 (1H, m, 
PCH), 3.91-3.85 (2H, m, CH2), 3.83 (3H, d, J = 10.5 Hz, OCH3), 3.82 (3H, d, J = 10.5 
Hz, OCH3); 13C NMR (125.6 MHz, CDCl3) δ 68.8 (CH, d, J = 160 Hz), 62.3, 53.3 
(OCH3, d, J = 24.9 Hz); 31P NMR (202.3 MHz, CDCl3) δ 26.9. (Stereospecific 
dihydroxylation by AD mix β yields enantiomerically enriched product, however, NMR 
experiments described in this report do not differentiate between enantiomers, and 
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therefore it was not necessary for this report to determine the enantiomeric excess of the 
product.)  
 
 1,2-Dihydroxyethylphosphonate monomethyl ester (5). To a 10 mL round-bottomed 
flask containing the ester 4 (167 mg, 0.982 mmol) was added 4.5 mL of acetone and the 
reaction was stirred at room temperature. To this suspension was added p-toluene 
sulfonic acid (9.3 mg, 5 mol%) and the mixture was stirred overnight. The temperature 
was raised on an oil bath, and the reaction mixture was refluxed for 2 h. After cooling 
down, the crude products were extracted with dichloromethane (3 × 40 mL), and the 
combined organic layer was dried over magnesium sulfate. Purification was achieved by 
silica gel column chromatography (EtOAc:MeOH = 10:1) to isolate a colorless oil. To 
this material was added 10% NaOH solution and the reaction was heated to 100 oC. After 
refluxing for 3 h, the reaction was acidified using 1 M HCl, and passed through a Dowex 
(H+) column to yield the desired acid in a 36.1% overall yield. 1H NMR (500 MHz, D2O) 
δ 3.75 (1H, td, J = 9.5, 2.5 Hz, PCHOH), 3.68 (1H, ddd, J = 12, 5.5, 2.5 Hz, CH2OH), 
3.50 (1H, ddd, J = 12, 9.5, 4.5 Hz, CH2OH), 3.45 (3H, d, J = 10.5 Hz, OCH3); 13C NMR 
(125.6 MHz, D2O)  δ 68.58 (d, J = 157 Hz, HOCHP), 61.84 (d, J = 9.2 Hz, POCH3), 
52.61 (d, J = 6.5 Hz, HOCH2); 31P NMR (202.3 MHz, D2O) δ 20.8. HRMS (ESI) calcd 
for C3H9O5NaP [M + Na]+ 179.0085 found 179.0078. 
 
1,2-Dihydroxyethylphosphonic acid (3). To a 50 mL round-bottomed flask were added 
91.8 mg (0.54 mmol) of the ester 7 and 5 mL of dry dichloromethane. While stirring at 
room temperature, bromotrimethylsilane (380 mg, 3.5 equiv) was added dropwise. After 
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stirring further at room temperature for 2 h, 2 mL of methanolic water was added. The 
excess solvents and reagents were removed under reduced pressure and after diluting 
with water, the product was mixed with charcoal and filtered through celite to obtain the 
desired product in a quantitative yield. 1H NMR (500 MHz, CDCl3) δ 3.68 (1H, ddd, J = 
10.0, 9.0, 3.0 Hz, PCH), 3.60 (1H, ddd, J = 12.0, 7.0, 3.0 Hz, CH2), 3.43 (1H, ddd, J = 
12.0, 9.0, 5.5 Hz, CH2); 13C NMR (125.6 MHz, D2O) δ 69.1 (HOCP, d, J = 156.2 Hz), 
61.9 (HOCH2, d, J = 8.8 Hz); 31P NMR (202.3 MHz, D2O) δ 21.3.  
 
1-Hydroxyethylphosphonate dimethyl ester. A solution of acetaldehyde (14.31 mmol) 
and dimethyl phosphite, 20 mmol) in dry diethyl ether (20 mL) was cooled to -42 oC, and 
a saturated solution of sodium methoxide (0.14 mmol) in methanol was added dropwise. 
The reaction mixture was stirred for 10 min, and the excess solvent and reagent were 
removed at reduced pressure. The crude products were extracted with EtOAc (3 × 30 mL), 
and the organic layer was dried over MgSO4. After filtering off the drying agent, solvent 
was removed on the rotovap to afford the desired product in near quantitative yield. 1H 
NMR (500 MHz, CDCl3) δ 4.08 (1H, dq, J = 7.0, 3.0 Hz, HOCH), 3.82 (6H, dd, J = 10.5, 
4.5 Hz, POCH3), 1.45 (3H, dd, J = 17.5, 7 Hz, CH3CHOH); 31P NMR (202.3 MHz, 
CDCl3) δ 29.0.  
 
1-Hydroxyethylphosphonate monomethyl ester. To a solution of dimethyl 1-
hydroxyethyl phosphonate ester (1.655 mmol), was added 10% NaOH dropwise while 
stirring. The reaction mixture was refluxed for 4.5 h. After cooling, the crude product was 
acidified with 1 M HCl, and extracted with chloroform (3 × 40 mL), and dried over 
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sodium sulfate. After the solvent was removed by reduced pressure, the desired product 
was obtained in near quantitative yield. . 1H NMR (500 MHz, CDCl3) δ 3.85 (1H, m, 
HOCH), 3.52 (3H, d, J = 10.5 Hz, POCH3), 1.17 (3H, dd, J = 9.5, 7.5, Hz, CH3CHOH); 
13C NMR (125.6 MHz, D2O) δ 63.2 (CHOH, d, J = 161.3 Hz), 52.5 (POCH3, d, J = 6.9 
Hz), 16.8 (CH3); 31P NMR (202.3 MHz, CDCl3) δ 27.0. HRMS (ESI) calcd for 
C3H9O4NaP [M + Na]+ 163. 0136 found 163.0141.  
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CHAPTER 4: CHARACTERIZATION OF A NOVEL PHOSPHONATE               
O-METHYLTRANSFERASE INVOLVED IN DEHYDROPHOS BIOSYNTHESIS 
 
4.1 – Introduction 
Phosphonic acids exhibit a range of biological activities due to their ability to 
mimic naturally prevalent compounds including phosphate esters (Figure 1.2A) and 
carboxylates (Figure 1.2B). Despite their ability to inhibit many enzymatic reactions 
related to therapeutic applications, phosphonic acids have not been fully explored as drug 
candidates. A general drawback of phosphonates is their high charge state at neutral pH, 
and therefore poor bioavailability, which renders them less than ideal for achieving high 
concentrations at the target site. Two different strategies are found in Nature to overcome 
these limitations. The first strategy can be found in phosphinothricin which mimics the 
tetrahedral intermediate generated in glutamine synthetase by using a phosphinate group 
containing two P-C bonds (Figure 1.2C).1,2 In an alternative solution, in dehydrophos the 
phosphonate group is esterified, a common approach in synthetic prodrugs3 but the first 
such example in a natural product (Figure 3.3).4  
The structure and biosynthesis of dehydrophos were discussed in the previous 
chapter of this dissertation. Dehydrophos contains a unique vinyl aminophosphonate 
moiety linked to a Gly-Leu dipeptide (Figure 3.3). The mode of action of dehydrophos is 
currently not known, but analogous to other peptide antibiotics, it is anticipated that after 
uptake by a peptide transporter, a peptidase will release the active phosphonate species.5,6 
The methyl ester of vinyl aminophosphonic acid, the hydrolysis product of the tripeptide, 
is believed to be responsible for the antibiotic activity of dehydrophos as this enamine 
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tautomerizes to an imine, and then undergoes spontaneous hydrolysis to form 
acetylphosphonic acid methyl ester, a potent inhibitor for pyruvate dehydrogenase.7     
One notable transformation in the biosynthetic pathway of dehydrophos is the 
unprecedented O-methylation of the phosphonic acid that results in the phosphonate 
monomethyl ester which is characteristic for dehydrophos. This transformation was 
hypothesized to be carried out by an S-adenosyl-L-methionine (SAM or AdoMet) 
dependent methyltransferase encoded by dhpI (Figure 4.1).8 Amino acid sequence 
searches using BLAST as well as conserved protein domain searches by InterProScan 
indicate that DhpI is a Type I methyltransferase utilizing SAM as a methyl donor. 
Previous structural studies have shown that this protein family forms a typical Rossman-
like alpha-beta fold. The ClustalW sequence alignments with proteins of known function 
show no sequence homology in the putative substrate binding domain, indicating that the 
substrate of this enzyme is unique to this protein. Although numerous SAM-dependent 
O-methyltransferases are known to methylate various functional groups including 
carboxylic acid and hydroxyl groups, the methylation of phosphonic acids by this group 
of enzymes has not been reported. The fact that methyl acetylphosphonate inhibits 
pyruvate dehydrogenase 125 times more potently than acetylphosphonate7 may provide a 
rationale for methylation in dehydrophos as a mean to improve its bioavailability and 
activity. 
In order to examine the substrate scope of DhpI, the phosphonate intermediates in 
the putative biosynthetic pathway were interrogated as potential substrates for DhpI. At 
the outset of my studies, the exact timing of the methyl transfer reaction was not clear as 
any of the intermediates shown in Figure 4.2 could be the natural substrate for this O-
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methyltransferase. With overexpressed and purified DhpI in hand, its enzymatic activity 
with various synthetic substrates could be studied. In parallel to the study of the DhpI 
reaction, several crystal structures of DhpI were produced by our collaborators to further 
elucidate the determinants of substrate recognition. With structural information, the 
amino acid residues in proximity to the substrate binding pocket site could be identified, 
and the roles of those residues were examined by site-directed mutagenesis in my work. 
Furthermore, the potential in applications of DhpI as a versatile biocatalyst have been 
demonstrated by showing the broad substrate tolerance in esterifying other biologically 
active phosphonates, such as the antibiotic fosfomycin and antimalarial agent 
fosmidomycin.
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Figure 4.1 Schematic diagram of the SAM-dependent methyl transfer reaction catalyzed 
by DhpI where a phosphonic acid is converted to a phosphonate methyl ester in the SAH 
nucleosidase coupled assay. AdoHcy, the by-product of the reaction is a strong product 
inhibitor.   
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4.2 – Results 
4.2.1. Expression and Purification of Recombinant Proteins for DhpI Assays. 
In order to investigate the methyltransferase activity, a recombinant system that 
allows production of DhpI in a soluble and easily isolatable form was prepared. The dhpI 
gene was cloned from Streptomyces luridus genomic DNA and inserted into the 
expression vector pET15b. DhpI was heterologously expressed in E. coli with an N-
terminal hexahistidine tag (His6-DhpI). The expression of the 26 kDa protein was 
achieved in E. coli Rosetta 2 (DE3), which is a BL21 DE3 derived strain that can supply 
tRNAs for rare codons not highly produced by E. coli. Successful purification by 
immobilized nickel affinity chromatography afforded an overall yield of 10-15 mg of 
purified His6-DhpI per liter of culture (Figure 4.2).  
In vitro reconstitution of DhpI activity was carried out in the presence of a 
coupling enzyme, SAH nucleosidase. Most of the reported SAM-dependent 
methyltransferases undergo a strong product inhibition by S-adenosyl-L-homocysteine 
(SAH or AdoHcy, Figure 4.1).9 This can be circumvented by either using a high 
concentration of SAM in the assay, or by removing SAH from the reaction mixture as 
soon as it is made. In this study the latter method was employed by using AdoHcy 
nucleosidase, which converts SAH to adenine and S-ribosylhomocysteine (Figure 4.1). 
The recombinant E. coli SAH nucleosidase was overexpressed as a fusion protein with an 
N-terminal hexahistidine tag in E. coli BL21, allowing facile purification by using Ni-
affinity column chromatography (Figure 4.2). In order to alleviate product inhibition 
from AdoHcy, SAH nucleosidase utilized in the assay is required to be highly efficient. 
The catalytic efficacy of E. coli SAH nucleosidase reported in the literature is 11.6 × 106 
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M-1 s-1, and in general the enzyme has much higher activity than that of most known 
methyltransferases.9 The efficacy of heterologously expressed and purified SAH 
nucleosidase was confirmed by LC-MS detection of the disappearance of the SAH peak 
(385, M+1) as well as by complete loss of the SAH signal in the diode array detector 
(DAD) coupled to HPLC. The SAH breakdown was observed only when SAH 
nucleosidase was present in the assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Typical overexpression and purification gel for DhpI and SAH nucleosidase. 
The 10% SDS-PAGE gels were stained with Coomassie Brilliant Blue. The size of the 
protein was determined by comparing to protein standards (PS = protein standard, BI = 
pre-induction sample, PI = post-induction sample, L = proteins in the lysed cell, FT = 
unbound proteins eluting from the Ni2+ column, W = wash fractions, E = proteins eluted 
from the IMAC column with buffer containing a high imidazole concentration).  
      BI       PI           E
His6‐SAH
nucleosidase 
(28 kDa) 
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4.2.2. In Vitro Reconstitution of Enzymatic Activity of DhpI.  
The first evaluation of the methylation activity of DhpI focused on the conversion 
of the early biosynthetic intermediates 2-HEP and 1,2-dihydroxyethylphosphonic acid 
(DHEP) to their monomethyl phosphonate esters, 2-HEP-OMe and DHEP-OMe. The 
methylated compound 2-HEP-OMe was previously shown to accumulate in the spent 
growth medium of some of the genetic mutants generated by B. Circello in the 
heterologous host Streptomyces lividans.8 2-HEP and DHEP were chemically synthesized 
as described in Chapter 3 and the rate of formation of the methyl ester products was 
determined by direct detection using HPLC coupled to atmospheric pressure chemical 
ionization mass spectrometry (APCI/MS) with synthetic compounds as authentic 
standards (Figure 4.3). Additional transformation to dimethyl phosphonate esters was not 
observed even after a prolonged reaction time. By direct comparison with the authentic 
sample of the methylated product, both 31P NMR spectroscopy and the fragmentation 
pattern in tandem MS confirmed that the methylation occurred on the oxygen of the 
phosphonic acid, and not on the hydroxyl  groups of DHEP and 2-HEP. 
Although both 2-HEP (Figure 4.3A) and DHEP were methylated by DhpI, they 
proved relatively poor substrates that were unable to saturate the enzyme even at high 
concentrations. N-Acetyl-1-aminoethylphosphonic acid (Ac-1-AEP or AcAlaP) was also 
converted to the corresponding methyl ester whereas little or no conversion was observed 
for 1-AEP and 2-AEP. Surprisingly, 1-hydroxyethylphosphonic acid (1-HEP) was a 
much better substrate (Table 4.1), and as discussed in Chapter 3 its methyl ester (1-HEP-
OMe) was also produced by some of the mutants of the producing strain.8 However, it is 
difficult to envision a biosynthetic pathway that would include this compound as an 
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intermediate, and 1-HEP-OMe could be a breakdown product of dehydrophos rather than 
a biosynthetic intermediate (see Chapter 3 for a detailed discussion). Collectively, these 
results suggested that a positive charge on either C1 or C2 is not tolerated for DhpI 
activity, and that DhpI may favor an amide group and an aliphatic substituent at the α-
carbon. Desmethyl dehydrophos satisfies both structural conditions, suggesting 
methylation might be the last step in the biosynthetic pathway (Figure 3.3). 
 
 
Table 4.1 Kinetic parameters for various substrates of DhpI. 
Substrates  Km, μM  kcat, s
‐1  kcat/Km, M
‐1∙ s‐1
DHEP  ‐  ‐  0.90 
2‐HEP  ‐  ‐  1.0 
1‐HEP  432 ± 36  (5.2 ± 0.17) x 10‐3  1.2 × 101 
Gly‐L‐Leu‐L‐AlaP  51 ± 7  (6.9 ± 0.26) x 10‐2  1.4 × 103 
Gly‐L‐Leu‐D‐AlaP  82 ± 4  (4.9 ± 0.068) x 10‐2  5.9 × 102 
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Desmethyl dehydrophos is not readily available using our previously described 
synthetic route to dehydrophos.4 Instead, both diastereomers of the hydrogenated analog 
of desmethyl dehydrophos were prepared using previously described methodology10 by 
Dr. Michael Kuemin. These peptides incorporate the well known phosphonate analog of 
alanine (AlaP; Figure 4.3). LC-MS analysis demonstrated that DhpI catalyzed the 
complete conversion of each of the diastereomeric peptides to their corresponding 
methylated derivatives (Figure 4.4A). The kcat/Km values of both diastereomers of Gly-L-
Leu-AlaP were approximately 100-fold larger than that of 1-HEP, which displays the 
highest kcat/Km among the other phosphonic acids tested (Figure 4.4B). The enzyme did 
not strongly differentiate between the two diastereomers of Gly-Leu-AlaP with Gly-Leu-
L-AlaP being slightly more active (2-fold higher kcat/Km) than Gly-Leu-D-AlaP. The 
absolute stereochemistry of one of these two diastereomers was determined by X-ray 
crystallography (for the crystal structure, please refer to ref.11). On the other hand, Gly-
Leu-SerP (Figure 4.3), also prepared by Dr. Kuemin and another potential intermediate in 
the dehydrophos biosynthetic pathway as a precursor to the vinyl group of dehydrophos, 
was a very poor substrate for DhpI.  
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Figure 4.3 Chemical structures of various phosphonate substrate candidates used in the 
DhpI assays.  
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Figure 4.4 LC-MS traces showing the DhpI-catalyzed conversion of (A) Gly-L-Leu-(D,L)-
AlaP to Gly-L-Leu-(D,L)-AlaP-OMe and (B) 2-HEP to 2-HEP-OMe.   
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A 
99 
 
 
 
 
 
 
 
Figure 4.5 Michaelis-Menten curve obtained by using variable concentrations of Gly-
Leu-L-AlaP (open circle) and Gly-Leu-D-AlaP (closed circle) at a saturated concentration 
of SAM (3 mM). 
 
Gly-L-Leu-L-AlaP 
Gly-L-Leu-D-AlaP 
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4.2.3. X-ray Crystal Structure of DhpI.*  
The crystal structures of DhpI have been solved in a collaborative effort with Dr. 
Brian Bae in the laboratory of Prof. Satish K. Nair (Department of Biochemistry, UIUC). 
One structure was in complex with the substrate SAM (2.3 Å resolution, DhpI-SAM) and 
one in complex with the product SAH (1.5 Å resolution, DhpI-SAH). Also the ternary 
complex of DhpI with both SAM and a substrate analogue 2-HEP (2.3 Å resolution, 
DhpI-SAM-2-HEP) could be obtained. The overall structure of DhpI consists of a 
Rossman-fold domain alternating between seven β-strands and six α-helices similar to 
other methyltransferases, and the N-terminus of the protein is located the SAM-binding 
site, and the substrate binding domain is present at the C-terminus,.  
A unique insertion is found between strand β5 and helix α6 of the Rossman-fold 
that covers the active site which distinguishes DhpI from the other methyltransferases. 
This insertion consists of a short helix and will be referred to as “capping helix” followed 
by two β-strands. Residues within this insertion appear to play critical roles in 
modulating product release following methyl transfer (Figure 4.6A).  DhpI forms a 
homodimer in the presence of SAM and sulfate (and presumably with phosphonate 
substrates). In the DhpI-SAM-SO42- co-crystal structure, the active site of one monomer 
is enclosed by the “capping helix” from an adjacent monomer, forming a domain-
swapped dimer (Figure 4.6B). In the crystal structure of DhpI-SAM, strong electron 
density corresponding to a sulfate molecule can be observed adjacent to the methyl group 
of SAM.  At the active site, several enzyme residues including Tyr15, His119, Arg168, 
                                                 
* This section on the crystallization of DhpI and the annotation of the crystal structures was performed by 
Dr. Brian Bae from the laboratory of Prof. Satish K. Nair (Department of Biochemistry, UIUC). More 
detailed discussions on the result and the methods of refinement can be found in the text and supporting 
information of ref.11 
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and Lys180 engage the sulfate anion (Figure 4.7), whose roles involved in catalysis were 
interrogated by mutational analysis discussed in the next section. The DhpI-SAM-SO42- 
co-crystal likely mimics the binding mode of SAM with phosphonic acid substrate, prior 
to methyl transfer. 
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Figure 4.6 X-ray crystal structure of DhpI. (A) Co-crystal structure of DhpI with SAM 
and SO42- showing a core Rossman-fold domain consisting of seven β-strands surrounded 
by six α-helices. A short helix and two β-strands shown in blue are referred to as the 
“capping helix”. (B)  DhpI-SAM-SO42- co-crystal showing its homodimer formation prior 
to the methyl transfer. These figures were prepared by Prof. Satish K. Nair and used with 
his permission. 
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Figure 4.7 Crystal structure of DhpI with sulfate anion coordinated to four amino acid 
residues Tyr 15, His 119, Arg 168, and Lys 180. This figure was prepared by Prof. Satish 
K. Nair and used with his permission. 
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 The overall co-crystal structure of DhpI-SAM and that of DhpI-SAH showed 
different crystal morphologies. DhpI-SAH is monomeric in the crystal and no electron 
density can be observed for the sulfate substrate to mimic in the active site. DhpI-SAM-
SO42- reveals a number of significant rearrangements near the substrate-binding site and 
at the “capping helix”. While SAH complex forms a continuous helix (Figure 4.8A), in 
the DhpI-SAM-SO42- structure residues Val27 through Tyr29 are rearranged to hift into 
the active site, resulting in a break in this helix (Figure 4.8B). Val27 interacts with the 
methyl group of SAM which facilitates the helix breakage, which is further facilitated by 
the presence of a proline residue (Pro28A) within the helix. This helix break results in 
inter-subunit interactions most notably Tyr29A with Glu155B (Figure 4.9A). These 
interactions facilitate additional inter-subunit hydrogen bond interactions that results in a 
second notable local conformational difference between the two structures, specifically a 
β-hairpin with residues Val166 through Val179 moves towards the active site in the 
DhpI-SAM-SO42- structure (Figure 4.8B), resulting in hydrogen bonding interactions 
between Arg153A and Asp149B, the main chain oxygens of Glu157A and Asp158A with 
Arg168B (Figure 4.9A), and Glu156A with the main chain oxygen of Gly207B. These 
interactions in the DhpI-SAM-SO42- structure may be involved in the stabilization of the 
inter-subunit interactions of the “capping helix” and result in the formation of a closed 
active site for securing the substrate in an optimal orientation for methyl transfer (Figure 
4.9A). Also, in DhpI-SAH complex, the “capping helix” are disordered and the 
continuous amino terminal helix orients Tyr29A toward the monomer, thereby disrupting 
interactions with Glu155B that would stabilize the “capping helix” (Figure 4.9B).   
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Figure 4.8 Comparison of co-crystal structures of DhpI with substrates and product. The 
picture was prepared by Prof. Satish K. Nair. (A) DhpI-SAH complex showing the 
continuous helix between His 5 and Leu 41. (B) DhpI-SAM-SO42- structure (orange) 
superimposed with DhpI-SAH structure (blue) showing a rearrangement from Val 27 
through Tyr 29 and β-hairpin shifting resulted from the helix break. 
A 
B 
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Figure 4.9 Comparison of the crystal structure of DhpI showing the inter-subunit 
interaction. The picture was prepared by Prof. Satish K. Nair. (A) The interactions 
between Tyr29A with Glu155B, and Asp158B with Arg168A are shown in the DhpI-SAM-
SO42-, which result in the formation of a closed active site. (B) DhpI-SAH structure 
where Tyr29A is now oriented toward the monomer, and the interaction with Glu155B no 
longer exists.  
A 
B 
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4.2.4. Study of DhpI Active Site by Site-directed Mutagenesis.  
In order to investigate the role of putative catalytic residues, several single point 
mutations were generated of residues that were in close proximity to the sulfate in the 
SAM co-crystal structure. The mutations were introduced by using Quick Change site-
directed mutagenesis method. In this method DNA primers that contain the desired 
mutation are used in the template-based DNA amplification by polymerase chain reaction 
(PCR). For DhpI mutants the whole plasmid, pET15b-dhpI construct, was used as a 
template, and this wild-type plasmid, which is not mutated, could later be eliminated by 
using a restriction enzyme specific for methylated DNA only found in biosynthesized 
DNAs in contrast to unmethylated, PCR-generated DNAs. The substitution of His119, 
Lys180, and Arg168 with Ala resulted in loss of methylation activity with the tripeptide 
substrates within the detection limits of our assays. Mutation of Tyr15 to Phe did not 
abolish activity but did greatly decrease kcat and increase Km, resulting in overall 1,000-
fold decrease in catalytic efficiency (Table 4.2). Therefore, all four residues are likely to 
be involved in the binding of the phosphonic acid moiety of the tripeptide substrate.  
In addition, the importance of two residues that appear to be critical for the 
disruption of the N-terminal helix in the SAM co-crystal structure and for setting up the 
sulfate binding pocket was investigated. Mutation of Val27 that makes Vanderwaals 
contacts to the methyl group of SAM to Ala had a modest effect, resulting in a fivefold 
decrease in kcat/Km. On the other hand, mutation of Tyr29, which due to the result of helix 
breakage, makes a contact with Glu155 of the other subunit, had a more pronounced 
effect. The kcat/Km value for the tripeptide substrate decreased about 500-fold compared 
to the wild type enzyme.   
108 
 
Table 4.2 The activity of DhpI mutants as expressed in kcat/Km of Gly-L-Leu-L-AlaP. 
DhpI WT 
and Mutants 
Km, μM
a  kcat, s
‐1  kcat/Km, M
‐1∙ s‐1 
WT  51 ± 7  (6.9 ± 0.26) x 10‐2  1.4 × 103 
R168A  ‐  ‐  Inactivea 
Y15F  742 ± 75  (9.4 ± 0.53) x 10‐4  1.3 
K180A  ‐  ‐  Inactivea 
H119A  ‐  ‐  Inactivea 
V27A  82 ± 19  (2.0 ± 3.5) x 10‐2  2.4 × 102 
Y29F  1270 ± 676  (3.6 ± 1.3) x 10‐3  2.8 
a No activity was observed within our detection limits. 
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4.2.5. Applications of DhpI in the Esterification of Phosphonic acids 
Given the improved pharmacokinetic properties of phosphonate esters compared 
to phosphonic acids, investigation of the substrate scope of DhpI was pursued. 
Encouraged by the observed broad substrate scope of DhpI, the enzymatic esterification 
of other naturally synthesized phosphonic acids which are known to exhibit interesting 
biological activities was tested. The enzyme assays were performed in a similar fashion 
as described previously, with LC-MS as the method of product detection. The enzyme 
was able to fully convert the anti-malaria clinical candidate fosmidomycin to its methyl 
ester (Figure 4.10A, 4.11A). Extracted ion chromatograms show the complete methylation 
of fosmidomycin within 24 h. Fosmidomycin, which has a retention time (RT) of 5.9 min 
(m/z 184) was not present, and instead a new peak which corresponds to monomethylated 
fosmidomycin (m/z 198) was observed with a RT of 9.4 min. Similarly, the clinically 
used antibiotic fosfomycin (RT = 6.1 min, m/z 139) was completely transformed to its 
methyl ester (RT = 9.1 min, m/z 153) by DhpI in less than 24 h (Figure 4.10B, 4.11B). 
The substrate promiscuity of the enzyme was also extended to L-(+)-2-amino-4-
phosphonobutyric acid (L-AP4, Figure 4.3), an often used non-hydrolizable analog of 
phosphoSer. Another interesting phosphonate that could be esterified by DhpI is methyl 
phosphonate. Collectively, these experiments demonstrate the promise of using DhpI or 
in vitro evolved analogs for bioengineering of esterified phosphonates.  
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Figure 4.10 Methylation of phosphonate natural products. Extracted ion chromatograms 
showing the complete methylation of fosmidomycin and fosfomycin as substrate of DhpI 
after 24 h of incubation. (A) Fosmidomycin (RT = 5.9 min, m/z 184) was fully converted 
to fosmidomycin-OMe (RT = 9.4 min, m/z 198). (B) Fosfomycin (RT = 6.1 min, m/z 
139) was fully converted to fosfomycin-OMe (RT = 9.1 min, m/z 153). IS = internal 
standard. 
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Figure 4.11 Mass spectra showing the methylation of fosmidomycin and fosfomycin by 
DhpI. Extracted ion chromatograms are shown that correspond to (M+H)+ of the 
substrate (blue), product (red), and the internal standard (IS), AcAsp (green). Insets 
show the mass spectrum at the retention times (RT) shown. (A) Fosmidomycin (RT = 
5.9 min, m/z 184) was fully converted to fosmidomycin-OMe (RT = 9.4 min, m/z 198). 
(B) Fosfomycin (RT=6.1 min, m/z 139) was fully converted to fosfomycin-OMe 
(RT=9.1 min, m/z 153). 
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Figure 4.11 (continued) 
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 The application of DhpI for alkylating phosphonic acids was further extended to 
utilization of the SAM analogue allyl-AdoMet (Figure 4.12), a SAM analogue prepared 
by Dr. Kuemin using chemical synthesis. In the LC-MS analysis of the assay, partial 
conversion of the phosphonate substrate, Gly-Leu-L-AlaP (RT = 9 min, m/z 296) to Gly-
Leu-L-AlaP-OAllyl (RT = 15 min, m/z 336) could be observed (Figure 4.13). This result, 
although quite preliminary, demonstrates the applicability of allyl-AdoMet as alkyl donor 
in DhpI-catalyzed alkylation reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Structure of AdoMet and its allyl analogue “allyl-AdoMet”. 
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Figure 4.13 Formation of monoallyl phosphonate ester, Gly-Leu-AlaP-OAllyl. Shown 
are the extracted ion chromatograms for the substrate (Gly-Leu-AlaP, M+1 = 296, blue 
chromatograms) with RT = 9 min and the proposed product (Gly-Leu-AlaP-OAllyl, M+1 
= 336, red chromatograms) with RT = 15 min. The samples were taken at 0 h and 10 h 
after the initiation of the reaction.  
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4.3 – Discussion and Conclusion 
PEP mutase installs the P-C bond in all phosphonates for which the gene clusters 
are currently known. A multidisciplinary team focused on naturally occurring 
phosphonates has recently demonstrated that the gene clusters of these compounds can be 
readily identified using the pepM gene as a marker.12-21 In addition, these studies have 
shown that phosphonate biosynthesis is widespread and that new clusters that encode for 
as yet structurally unidentified phosphonates are readily found.22 Given the range of 
biological activities that known phosphonates display and given their current applications 
in medicine and agriculture, these unidentified phosphonates may provide a reservoir for 
new compounds with useful activities. As noted, the bisanionic charge state of 
phosphonates provides a potential hurdle for their use, a drawback that in synthetic 
phosphonates is circumvented by esterification. Dehydrophos is currently the only known 
esterified naturally occurring phosphonate and DhpI is the only SAM-dependent O-
methyltransferase that transfers the methyl group to a phosphonate moiety.  
In this study, we identified tripeptides closely resembling desmethyl dehydrophos 
as the preferred substrates of the enzyme, strongly suggesting it acts as the last step in the 
biosynthetic pathway to dehydrophos. This observation argues against one of the 
suggested roles of the methyl ester: as a protective measure to prevent the biosynthetic 
intermediates from inhibiting endogenous enzymatic reactions in the producing strain. 
Instead, introduction of the methyl group in the last step suggests that the methyl group is 
important for biological activity on other surrounding organisms. Acetylphosphonate 
methyl ester, the expected breakdown product after hydrolysis of the amide bonds of 
dehydrophos within the targeted organism, is a known inhibitor of pyruvate oxidase and 
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the esterified compound is a 125-fold better inhibitor than acetylphosphonate itself.7 
Thus, our current hypothesis for methylation is to provide a better mimic of the 
monoanionic pyruvate substrate. Further analysis with both diastereomers of the Gly-
Leu-SerP tripeptide did not display good activity in DhpI catalyzed methylation reaction, 
eliminating the possibility that the methylation takes place prior to phosphorylation and 
elimination. Instead, the hydroxyl group on the beta carbon in Gly-Leu-SerP may create a 
steric and/or electronic perturbation in the active site of DhpI, as all the other substrates 
with high conversion rate contained hydrophobic residues. Otherwise, DhpI displayed 
broad substrate specificity and methylated two clinically important phosphonate natural 
products. As such, it may prove to be a very useful biocatalyst to prepare methylated 
analogs of naturally occurring phosphonates by fermentation in engineered organisms. In 
addition, this study shows that the SAM analogue allyl-AdoMet can also be used to 
alkylate phosphonates using DhpI. Not only does this observation suggest broad utility of 
DhpI as an alkylating agent for phosphonate compounds, but this work also sets a stage 
for further exploitation of DhpI as a tool for the identification of unknown phosphonates 
as well as for their purification from cellular metabolites by using keto-AdoMet as 
methyl donor and subsequent use of the installed keto group as a handle in bioorthogonal 
reactions for labeling or tagging the unknown compounds.  
In addition to providing important new information regarding the biosynthesis of 
dehydrophos and showing promise for use as a biocatalyst, our work also uncovered 
unique mechanistic insights into DhpI catalysis. The three co-crystal structures illustrate 
an unusual conformational change that is triggered by the presence of both the methyl 
group of SAM and bound sulfate/phosphonate.  As both the SAM and SAH co-crystals 
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were grown under identical conditions (i.e. equivalent sulfate concentrations), the 
presence of the anion in only the SAM complex argues that the presence of the methyl 
group instigates the structural rearrangements that are further stabilized by substrate 
binding. The movement of Val27 in towards the active site in the DhpI-SAM-SO42- 
structure provides a solvent-excluded binding pocket for the methyl group.  This 
movement disrupts the continuous helix containing Val27 that is seen when SAH is 
present and is likely aided by the presence of Pro28. The energetic penalty for disrupting 
the helix is compensated by four new intersubunit interactions that stabilize the capping 
helix. Mutation of Val27 to Ala resulted in only a five-fold decrease in the catalytic 
efficiency over the wild-type, indicating that the Vanderwaals interaction between Val27 
and the methyl group of SAM provides only a limited energetic driving force for the 
structural rearrangement. It is likely that additional energy may be provided by the 
electrostatic interaction between the negatively charged sulfate/phosphonate group and 
the positively charged sulfonium group of SAM. In the SAH structure, these interactions 
are likely destabilizing, favoring the continuous helix and disrupting the extensive 
intersubunit interactions and preventing the stabilization of the sulfate/phosphonate 
binding pocket.   
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4.4 - Experimental Procedures 
4.4.1. Preparation of DhpI Mutants  
General Materials and Methods for Site-directed Mutagenesis. All molecular biology 
techniques, including PCR, transformation and plasmid preparation, were performed 
using standard procedures.23 The amino acid mutations were introduced by the Quick-
Change method as described in the Stratagene manufacturer’s guide. DpnI was purchased 
from Invitrogen (Carlsbad, CA), and the oligonucleotides used for mutations were 
purchased from IDT. PCR amplifications were performed using an automated 
thermocycler (PTC 150, MJ Research). Plasmid isolation was accomplished by Qiagen 
Miniprep kits (Valencia, CA). Chemically competent E. coli DH5α cells were purchased 
from the University of Illinois at Urbana-Champaign (UIUC) Cell Media Facility. 
Sequencing reactions were performed at the W.M. Keck Center for Biotechnology at the 
University of Illinois at Urbana-Champaign utilizing standard T7 forward and reverse 
primers (T7-for/T7-rev). Chemically competent E. coli DH5α cells were transformed 
with each ligation mixture and plated on Luria-Bertani (LB)-agar containing the 
appropriate antibiotic to select for positive clones. For pET15b constructs ampicillin 
(Sigma-Aldrich) was used at 100 μg/mL concentration. 
 
Preparations of pET15b-dhpI (R168A) [JHL-VII-81, 89], pET15b-dhpI (Y15F) [JHL-IX-
6], pET15b-dhpI (K180A) [JHL-IX-8], pET15b-dhpI (H119A) [JHL-IX-8]. The construct 
pET15b-dhpI was obtained from Benjamin T. Circello from the laboratory of Prof. 
William W. Metcalf (Department of Microbiology, UIUC). Single point mutations were 
introduced by the QuickChange site-directed mutagenesis method using Pfu DNA 
polymerase and pET15b-dhpI wild type DNA as template for PCR. The oligonucleotide 
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primers were designed to contain mutation coding gene sequences (Table 4.3). Wild type 
DNA in the pET15b vector, which was isolated from E. coli was dam methylated and 
therefore could be digested by DpnI endonucleases leaving only DNA obtained by PCR 
in circular plasmid form. The E. coli DH5α strain was transformed with the DNA that 
contained the desired mutation.    
  
 
 
 
Table 4.3 Oligonucleotides used in the QuickChange site-directed mutagenesis of DhpI.  
 
Oligonucleotide DNA sequence 
DhpI WT FOR 
DhpI WT REV 
DhpI R168A FOR 
DhpI R168A REV 
DhpI Y15F FOR 
DhpI Y15F REV 
DhpI K180A FOR 
DhpI K180A REV 
DhpI H119A FOR 
DhpI H119A REV 
DhpI V27A FOR 
DhpI V27A REV 
DhpI Y29F FOR 
DhpI Y29F REV 
5’-GGATCCGAAGGAAAGCTTCATATGACCACTTCGCACGG-3’ 
5’-GGCGCGCCAGATCTGAATTCTCACCGCGGTCCGGGGCGGCACG-3’ 
5’-CCCGAGGTCGCCGTCCGCGCCACCCTCCAGGACGGGCGC-3’ 
5’-GCGCCCGTCCTGGAGGGTGGCGCGGACGGCGACCTCGGG-3’ 
5’-GGAGGCCCGGGCCCGGAAGTAGGACAGCTGGCTCTCGATCAGACC-3’ 
5’-GAGAGCCAGCTGTCCTACTTCCGGGCCCGGGCCTCC-3’ 
5’-CGCAGCTTCCGCATCGTGGCGGTCTTCCGCAGCCCGGCC-3’ 
5’-GGCCGGGCTGCGGAAGACCGCCACGATGCGGAAGCTGCG-3’ 
5’-GCCCACTGGCTGGCCGCTGTGCCCGACGACCGG-3’ 
5’-CCGGTCGTCGGGCACAGCGGCCAGCCAGTGGGC-3’ 
5’-TACGACGCGACCTTCGCGCCGTACATGGACTCC-3’  
5’-GGAGTCCATGTACGGCGCGAAGGTCGCGTCGTA-3’ 
5’-GCGACCTTCGTGCCGTTCATGGACTCCGCGGCG-3’  
5’-CGCCGCGGAGTCCATGAACGGCACGAAGGTCGC-3’ 
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4.4.2. Expression and Purification of DhpI and SAH nucleosidase  
E. coli Rosetta2 (DE3) cells harboring the DhpI-encoding plasmid were grown in 
a Luria-Bertani (LB) medium supplemented with antibiotic markers (100 μg/mL 
ampicillin and 20 μg/mL chloramphenicol) at 37 °C until OD600 reached 0.5 - 0.7. The 
expression of N-terminally His6-tagged DhpI was induced by addition of isopropyl-1-
thio-β-D-galactoside (IPTG) to 0.5 mM and the cells were continued to grow at 18 °C for 
15 h. The protein was purified by nickel-nitrilotriacetic acid (Ni-NTA) affinity 
chromatography (Qiagen, Valencia, CA). In a typical purification of the expressed 
proteins, E. coli cells from a 3 L culture were harvested by centrifugation at 5,000 × g for 
15 min at 4 °C. The cell pellet was resuspended in 30 mL of ice cold buffer A (50 mM 
Tris·HCl, pH 7.5, 100 mM NaCl, 10 mM imidazole) supplemented with 0.4 mg/mL 
lysozyme and protease inhibitor cocktail tablets (Complete Mini, EDTA-free, Roche), 
and cells were disrupted in a chilled French press cell at 15,000 psi. The cell lysate was 
cleared by centrifugation at 25,000 × g for 30 min at 4 °C, and the cleared soluble 
fraction was loaded on a column containing 8 mL Ni-NTA affinity resin (Qiagen, 
Valencia, CA) equilibrated with buffer A. After the loaded sample was loaded onto the 
column, unbound proteins were washed from the column with 10 column volumes of 
buffer B (50 mM Tris·HCl, pH 7.5, 100 mM NaCl, 20 mM imidazole) to remove any 
proteins nonspecifically bound to the column. Elution of the protein was achieved with 
buffer C (50 mM Tris·HCl, pH 7.5, 100 mM NaCl, 50-500 mM imidazole) with 
increasing imidazole concentrations in a step gradient from 50 mM to 500 mM with 30 
mM increments with a total elution volume of 200 mL. The elution fractions containing 
the desired protein as detected by SDS-PAGE gels stained with Coomassie Brilliant Blue 
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were concentrated by ultrafiltration using an Amicon Ultra 10 kDa membrane 
(Millipore). Imidazole and excess salt were removed by passage over a PD-10 column 
(GE Healthcare) pre-packed with Sephadex G-25. The protein was eluted from the 
column with buffer D (50 mM Tris·HCl, pH 7.5, 100 mM NaCl, 20% (w/v) glycerol), 
and the purified protein was flash frozen and stored at – 80 °C. Protein concentration was 
determined by Bradford assay following the standard protocol using bovine serum 
albumin as a standard protein. The overall yield of >95% pure protein obtained ranged 
between 10-15 mg per liter of culture.23 For the SAH nucleosidase, the DNA construct 
which encodes for N-terminally hexahistidine-tagged protein was generously provided by 
Prof. John E. Cronan (Department of Microbiology, UIUC), and the overexpression and 
purification was carried out in similar fashion as described for DhpI. 
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4.4.3. Preparation of Substrates and DhpI Activity Assay 
Syntheses of 2-HEP, 1-HEP, 1,2-DHEP, Ac-1-AEP, and their monomethylated 
phosphonate esters were carried out by myself, and are outlined in Chapter 3. 
Compounds 1-AEP, 2-AEP, and L-AP4 were commercially available. Syntheses of the 
tripeptide Gly-Leu-AlaP, its methylated product and Gly-Leu-SerP were achieved by a 
postdoctoral fellow, Dr. Michael Kuemin who also prepared the SAM analogues 
including Allyl-AdoMet (See reference 11 for details of the synthesis of the tripeptide).  
Enzyme kinetic assays were carried out at 30 °C in 50 mM Tris·HCl (pH 7.8) in 
1.5 mL reaction vials. The reaction mixture contained 3 mM AdoMet, 2 - 24 μM DhpI, 1 
μM AdoHcy nucleosidase, and 30 – 2000 μM phosphonate substrates in a final volume of 
300 μL. After adding DhpI, the reaction mixture was preincubated at 30 °C for 3 min 
before the reaction was initiated by addition of AdoMet. For quantification, 30 μL 
aliquots of the assay mixture were removed at designated time points and quenched with 
an equal volume of 0.1% formic acid containing 200 μM acetylated aspartate (AcAsp) as 
internal standard (IS) for quantification during LC-MS analysis. The assay sample was 
injected to a Synergi C18 RP-fusion column (150 mm × 4.6 mm, Phenomenex) on a 
HPLC system (Agilent Technologies 1200 series) equipped with a multimode 
electrospray ionization/APCI spray chamber. HPLC parameters were as follows: column 
temperature of 25 °C; solvent A, 0.1% formic acid in water; solvent B, methanol; for 
non-peptide phosphonates: isocratic mobile phase of 100% solvent A, for tripeptide-like 
phosphonates: gradient from 100% A to 30% B over 13 min; flow rate, 0.5 ml/min; 
detection by APCI/MS operating in a positive-ion mode. 
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4.4.4. MS Data Processing and Kinetic Analysis  
For each sample, the eluting fractions from HPLC were ionized by APCI and the 
mass spectrum was detected in positive ion mode. Relative intensities were determined 
by integrating the selected ion chromatogram for a specific ion across the entire elution 
profile. Quantification of each analyte was achieved by constructing a standard curve of 
chemically synthesized authentic sample. Each signal was normalized with a response 
factor (i.e. ratio of the integrated area of the analyte peak to the integrated area of the 
internal standard, AcAsp) to account for variations arising from the instrument and 
sampling conditions. The initial rates of the enzyme reactions were plotted for at least 
eight varying concentrations of substrates, and fitted to the Michaelis-Menten equation 
using nonlinear regression (KaleidaGraph program, ver.3.5) to estimate the apparent 
steady-state rate constants. All of the assays used for determination of kcat and Km were 
performed in duplicate.   
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